Category Archives: Industry Insights / 行业洞察

Pharma and biotech opening moves from the foreign-investment action plan: segmented production, pilot expansion and the payment chain

  • The Action Plan for Stabilising and Optimising the Utilisation of Foreign Investment (商资发〔2026〕97号, issued 16 June 2026 by MOFCOM, NDRC and MOF) commits the government to “expedite the study and issuance of implementation rules for segmented pharmaceutical production”, easing cross-border segmented manufacturing of biologics and chemical drugs by foreign marketing-authorisation holders.
    商务部、国家发展改革委、财政部《利用外资固稳促优行动方案》(商资发〔2026〕97号,2026年6月16日印发)明确”抓紧研究出台药品分段生产实施细则”,便利境外药品上市许可持有人开展生物制品、化学药品跨境分段生产。
  • The same plan moves to widen pilot geography: authorities will “expedite research and approval to further expand the pilot regions for biotechnology and wholly foreign-owned hospitals” — the two most-watched restricted-service openings of the current cycle.
    同一方案还推动试点扩围:”抓紧研究报批进一步扩大生物技术、外商独资医院领域开放试点区域范围”——这是本轮最受关注的两项限制性服务业开放。
  • The statutory base is already in place: the revised Drug Administration Law Implementation Regulations (published January 2026) turned segmented production from pilot into institution, letting marketing-authorisation holders commission qualified producers to segment-manufacture innovative drugs and clinically urgent drugs when genuinely needed, under a unified quality-assurance system covering all sites.
    法定底座已经就位:修订后的《药品管理法实施条例》(2026年1月公布)把分段生产从试点推向制度——药品上市许可持有人确有需要的,可委托符合条件的企业分段生产创新药、临床急需药品等,并建立覆盖全部生产场地的统一质量保证体系。
  • Commercial proof-of-concept has landed: in May 2026 Johnson & Johnson’s niccalimab injection became the first imported biologic to run domestic segmented production of drug substance in China, with the substance made by WuXi Bio in Wuxi and fill-finish completed in Germany.
    商业验证已经落地:2026年5月,强生制药的尼卡利单抗注射液成为全国首个开展原液境内分段生产的进口生物制品——原液由无锡药明生物生产,制剂在德国完成。
  • Biotech opening pilots are producing registrable outcomes: under the 2024 pilot allowing FIEs to develop and apply human stem-cell and gene diagnosis and therapy technologies in designated free trade zones, at least six foreign companies — including Merck, JW Therapeutics-related entities, Frontera Therapeutics and StarCellBio — have completed registration changes or new filings.
    生物技术开放试点已产出可登记成果:在2024年允许外商投资企业于指定自贸区开展人体干细胞、基因诊断与治疗技术开发应用的试点下,至少6家外资企业(含默克、药明巨诺相关主体、芳拓生物、星奕昂等)已完成经营范围变更或新设登记。
  • Payment and channel measures complete the chain: the plan supports insurers in covering more innovative drugs and devices under commercial health insurance, and calls for an industry collaboration platform to smooth foreign-made pharmaceuticals into retail channels — the “last mile” that has capped foreign pharma revenue in China.
    支付与渠道措施补齐链条:方案支持保险公司将更多创新药械纳入商业保险保障范围,并搭建行业协作平台便利外资企业生产的药品进入零售渠道——这正是此前封顶外资药企中国收入的”最后一公里”。

Pharma and biotech opening moves from the foreign-investment action plan: segmented production, pilot expansion and the payment chain | 外资行动方案中的医药开放组合:分段生产、试点扩围与支付渠道

Overview

The Action Plan for Stabilising and Optimising the Utilisation of Foreign Investment (《利用外资固稳促优行动方案》, 商资发〔2026〕97号), issued on 16 June 2026 by the Ministry of Commerce, the National Development and Reform Commission and the Ministry of Finance with State Council consent, devotes one of its fifteen measures to pharmaceuticals. The measure assembles a “production — marketing-authorisation — payment — channel” package for foreign pharmaceutical and biotech companies: segmented production implementation rules, expanded pilot geography for biotechnology and wholly foreign-owned hospitals, commercial-insurance payment support, and retail-channel facilitation.

With September 2026 commentary from the Shanghai government’s weekly foreign-invested information service now tracking the package in detail, the measures are the clearest single statement of where foreign pharma market access in China is heading this cycle.

Segmented production: from pilot to statute to rules

Segmented production (分段生产) distributes a drug’s manufacturing process across sites or companies — globally common, but long restricted in China. The progression:

  • October 2024: the National Medical Products Administration issued the pilot work plan for segmented production of biologics, allowing certain innovative and clinically urgent biologics to run segmented production at the pilot stage.
  • January 2026: the State Council published the revised Drug Administration Law Implementation Regulations, moving segmented production into institution. Article 31 provides that where a marketing-authorisation holder genuinely needs it, the holder may commission qualified manufacturers to segment-manufacture (i) innovative drugs with special process, facility or equipment requirements, (ii) clinically urgent drugs and drugs needed for public-health response or reserves identified by the State Council departments, and (iii) other drugs specified by the drug regulator. The holder must build a unified quality-assurance system covering the whole production process and all sites; vaccines and blood products carry their own commissioning rules.
  • Next step: the action plan’s commitment to issue implementation rules for segmented pharmaceutical production — the operational layer for application conditions, quality-responsibility allocation and regulatory coordination.

The commercial template already exists: in May 2026, Johnson & Johnson’s niccalimab injection became the first imported biologic to run domestic segmented production of drug substance — substance produced by WuXi Biologics in Wuxi, fill-finish completed by Vetter Pharma in Germany. For multinationals, the case demonstrates the operating model the rules will generalise: foreign marketing-authorisation holders placing upstream segments with qualified Chinese CDMOs while keeping downstream finishing abroad, or the reverse.

Biotechnology and wholly foreign-owned hospitals: pilot expansion pending approval

Biotechnology (human stem cells, gene diagnosis and therapy) has been open to FIEs only inside designated pilot areas since September 2024, when Beijing, Shanghai and Guangdong free trade zones and Hainan were authorised. The registry shows results: at least six foreign companies — including Merck, entities associated with JW Therapeutics (药明巨诺), Frontera Therapeutics (芳拓生物) and StarCellBio (星奕昂) — have completed business-scope changes or new registrations inside the pilot areas.

The action plan instructs authorities to expedite research and approval for expanding the pilot regions for both biotechnology and wholly foreign-owned hospitals — the same two openings that Shanghai’s 15th Five-Year plan and other provincial documents name as landing priorities. Neither expansion has been formally approved yet; the plan converts the expansion from discussion item into an official workstream with a deadline pressure attached.

Payment and channels: the last-mile package

Two measures address the revenue side that has historically capped foreign pharma’s China performance:

  • Commercial insurance. The plan supports insurers in bringing more innovative drugs and devices into commercial health-insurance coverage — the payer channel that has grown fastest as national reimbursement negotiations compress prices.
  • Retail channels. An industry collaboration platform will be built to facilitate foreign-produced pharmaceuticals entering drug retail channels — addressing the distribution friction that has kept foreign-manufactured drugs out of pharmacy chains even after approval.

What this means for foreign pharma and healthcare groups

  • Map your product portfolio against segmented-production eligibility. The statutory categories are innovative drugs with special process/equipment requirements and clinically urgent or reserve drugs; groups with biologics or special-technology chemicals should identify candidates and pre-qualify Chinese CDMO partners under a unified quality system.
  • Watch the implementation rules, not just the plan. Application conditions, quality-responsibility division and regulatory coordination sit in the forthcoming rules; the drafting is the moment to submit practical comments.
  • Treat pilot expansion as a siting decision. If the biotech and wholly-owned-hospital pilots extend to new provinces, entity location inside a pilot area becomes a structuring variable; hold new China healthcare investments until the expanded map is published.
  • Build the commercial-insurance and retail strategy now. Payment support and retail-channel facilitation are revenue-side measures; groups that prepare health-insurance dossiers and pharmacy distribution agreements can move when the platforms land.
  • Benchmark against the niccalimab case. The first segmented-production precedent defines the documentation and quality-system expectations regulators will apply to the next applications.

Sources

  • 济源产城融合示范区管理委员会(转载)— 商务部 国家发展改革委 财政部关于印发《利用外资固稳促优行动方案》的通知(商资发〔2026〕97号,2026年6月16日,政府官网全文): https://zt.www.jiyuan.gov.cn/zsyz/wstz_zsyz/zcfb/t1008712.html
  • 上海市人民政府外事办公室 — 《上海资讯周报》涉外资讯一站式服务(2026年9月第1期,总第157期,2026年9月2日,医药开放组合与分段生产制度演进综述): https://wsb.sh.gov.cn/ztzl/shzxzb/20260902/d2eb54ce238e4d6d9f5bcac6e428f6e6.html
  • 蒙城县人民政府(转载)— 中华人民共和国药品管理法实施条例(2026年修订版分段生产条款第31—33条全文): https://www.mengcheng.gov.cn/XxgkContent/show/3008349.html

Related reading

  • see also: segmented pharma production pilot mechanics (segmented-pharma-production)
  • see also: wholly foreign-owned hospital pilot requirements (foreign-owned-hospital-pilot)

外资行动方案中的医药开放组合:分段生产、试点扩围与支付渠道

概述

《利用外资固稳促优行动方案》(商资发〔2026〕97号)由商务部、国家发展改革委、财政部经国务院同意于2026年6月16日印发,其十五条举措中专设一条指向医药。该条为外资医药与生物技术企业组装了一套”生产—上市许可—支付—渠道”组合:分段生产实施细则、生物技术与外商独资医院试点扩围、商业保险支付支持与零售渠道便利。

随着2026年9月上海市政府涉外资讯周报对该政策包作出详细追踪解读,这是本周期内中国外资药品准入走向最清晰的一份单项表述。

分段生产:从试点到法定再到细则

分段生产(分段生产)把药品生产过程分布在不同场地或企业之间——全球通行,但在中国长期受限。演进脉络:

  • 2024年10月: 国家药监局印发生物制品分段生产试点工作方案,允许部分创新生物制品和临床急需生物制品在试点阶段开展分段生产。
  • 2026年1月: 国务院公布修订后的《药品管理法实施条例》,把分段生产推向制度。第三十一条规定,药品上市许可持有人确有需要的,可以委托符合条件的药品生产企业分段生产:(一)生产工艺、设施设备有特殊要求的创新药;(二)临床急需药品、应对突发公共卫生事件急需或储备需要的药品;(三)国务院药品监督管理部门规定的其他药品。持有人须建立覆盖药品生产全过程和全部生产场地的统一质量保证体系;疫苗、血液制品另有委托生产规则。
  • 下一步: 行动方案承诺出台药品分段生产实施细则——即申请条件、质量责任划分与监管协调的操作层。

商业模板已经出现:2026年5月,强生制药的尼卡利单抗注射液成为全国首个开展原液境内分段生产的进口生物制品——原液由无锡药明生物生产,制剂由德国Vetter Pharma完成。对跨国药企而言,该案例演示了细则将要推广的运营模式:境外持有人把上游环节放在中国合格CDMO、下游制剂留在境外,或反向操作。

生物技术与外商独资医院:扩围报批中

自2024年9月北京、上海、广东自贸区和海南获准试点以来,生物技术(人体干细胞、基因诊断与治疗)仅对试点区域内FIE开放。登记情况已有产出:至少6家外资企业——包括默克、药明巨诺相关主体、芳拓生物(Frontera Therapeutics)、星奕昂等——已在试点区域内完成经营范围变更或新设登记。

行动方案要求抓紧研究报批进一步扩大生物技术、外商独资医院领域开放试点区域范围——上海”十五五”规划等省级文件点名的同样是这两项开放。扩围尚未正式获批;方案把扩围从讨论事项转为带时限压力的正式工作流程。

支付与渠道:最后一公里

两项措施指向历史上封顶外资药企中国收入的收入端:

  • 商业保险。 方案支持保险公司将更多创新药械纳入商业健康保险保障范围——在国家谈判压缩价格背景下增长最快的支付通道。
  • 零售渠道。 将搭建行业协作平台,便利外资企业生产的药品进入药品零售渠道——解决获批外资药品难以进入连锁药店的流通摩擦。

对外资医药与医疗集团的启示

  • 对照分段生产法定情形梳理产品组合。 法定类别是工艺设施有特殊要求的创新药与临床急需、储备药品;拥有生物制品或特殊工艺化学药的企业应识别候选产品,并按统一质量体系预审中国CDMO伙伴。
  • 盯细则而不止于方案。 申请条件、质量责任划分与监管协调都在即将出台的实施细则中;起草阶段是提交实务意见的窗口。
  • 把试点扩围当作选址变量。 若生物技术与独资医院试点扩展至新省份,主体落位在试点区域内就成为架构变量;新医疗投资可等扩围地图公布后再定。
  • 现在就建商保与零售策略。 支付支持与渠道便利是收入端措施;提前准备健康险材料与药店分销协议的集团,可在平台落地时立即行动。
  • 对标尼卡利单抗案例。 首个分段生产先例界定了监管对后续申请的单证与质量体系预期。

来源

  • 济源产城融合示范区管理委员会(转载)— 《利用外资固稳促优行动方案》通知全文(商资发〔2026〕97号): https://zt.www.jiyuan.gov.cn/zsyz/wstz_zsyz/zcfb/t1008712.html
  • 上海市人民政府外事办公室 — 《上海资讯周报》涉外资讯一站式服务(2026年9月第1期): https://wsb.sh.gov.cn/ztzl/shzxzb/20260902/d2eb54ce238e4d6d9f5bcac6e428f6e6.html
  • 蒙城县人民政府(转载)— 中华人民共和国药品管理法实施条例(分段生产条款全文): https://www.mengcheng.gov.cn/XxgkContent/show/3008349.html

相关阅读

  • 见:药品分段生产试点机制要点(segmented-pharma-production)
  • 见:外商独资医院试点要求(foreign-owned-hospital-pilot)

China professionalises the hospital channel for medical-nutrition foods: the FSMP Guiding Opinions

  • In late August 2026, the National Health Commission (NHC) and SAMR jointly issued the Guiding Opinions on Regulating the Use of Foods for Special Medical Purposes (FSMP) in Medical Institutions (document 国卫办食品发〔2026〕11号, dated 6 August 2026).
    2026年8月下旬,国家卫生健康委办公厅与市场监管总局办公厅联合印发《关于规范医疗机构特殊医学用途配方食品使用的指导意见》(国卫办食品发〔2026〕11号,成文日期2026年8月6日),面向各级各类医疗机构。
  • The Opinions define FSMP as formula foods registered by SAMR for sale on the domestic market, formulated for people with restricted eating, digestive-absorption disorders, metabolic disorders or specific disease states, and require use under the guidance of a physician or clinical nutritionist.
    指导意见界定:特医食品是指经国家市场监管部门注册可以在国内市场销售、为满足进食受限、消化吸收障碍、代谢紊乱或特定疾病状态人群对营养素或膳食的特殊需要专门加工配制的配方食品,须在医师或临床营养技师指导下使用。
  • Medical institutions must set up a dedicated FSMP management department or group, maintain a dynamic internal supply catalogue admitting only SAMR-registered products, and centralise selection, procurement, use and charging.
    医疗机构须确立特医食品使用管理部门或小组,建立并动态调整本机构《特殊医学用途配方食品供应目录》,只允许经国家注册的特医食品进入目录,并对遴选、采购、使用、收费进行集中统一管理。
  • Within hospitals, FSMP must be sold in a clearly marked dedicated zone or counter (“特殊医学用途配方食品销售专区/专柜”), sale and usage information must be recorded and retained to medical-record standards, and FSMP must not be prescribed as medicine — it is not a drug, so no prescriptions, and billing must be separated from pharmaceuticals.
    院内管理上,特医食品须设专区专柜销售并显著提示;销售信息(含患者信息、品名、规格、价格)记录保存时限参照病历;特医食品不属于药品、不得开具处方,发放与收费须与药品区分。
  • For imported and domestic FSMP producers and their distributors, the guidance professionalises the hospital channel: registration status will be verified at the hospital gate, procurement and recall co-operation with institutions is formalised, and marketing into hospitals must shift from prescription-style promotion to compliance-based clinical-nutrition education.
    对国内外特医食品企业与经销商而言,新规使医院渠道走向专业化:注册资质在医院门口被核验,采购与召回配合被制度化,面向医院的推广须从”类处方”促销转向合规的临床营养教育。

China professionalises the hospital channel for medical-nutrition foods: the FSMP Guiding Opinions | 特医食品医院渠道走向规范化:两部门出台医疗机构使用指导意见

Overview

The National Health Commission (NHC) and the State Administration for Market Regulation (SAMR) jointly issued the Guiding Opinions on Regulating the Use of Foods for Special Medical Purposes (FSMP) in Medical Institutions (《关于规范医疗机构特殊医学用途配方食品使用的指导意见》) in late August 2026, with the document dated 6 August 2026 and publicised around 26–30 August. The Opinions, issued under the Food Safety Law and the Regulations on the Administration of Medical Institutions, apply to the selection, sale and use of FSMP within all types and levels of medical institutions in China. They mark the first time the national authorities have set out a complete operational framework for how hospitals should manage, stock, sell and use FSMP — a category that sits at the intersection of food, nutrition and clinical care.

What FSMP are — and why they need special rules

FSMP are formula foods that have been registered by SAMR for sale on the domestic market, specially processed and formulated to meet the nutritional or dietary needs of people with restricted eating, digestive or absorption disorders, metabolic disorders, or specific disease states. They provide important nutritional support for treatment, rehabilitation and maintenance of bodily function in these populations. Because they look like medical products but are legally food, they have historically sat in an ambiguous zone: food law governs their registration, yet their practical use is clinical, and hospitals have lacked uniform rules on procurement, pricing, storage and use.

The Opinions restate the fundamental boundary: FSMP must be used under the guidance of a physician or clinical nutritionist, and they are not drugs. The document applies to medical institutions holding a Medical Institution Practicing Licence or clinic-filing certificate.

Three layers of institutional rules

1. Governance structure. Each medical institution must establish a dedicated FSMP management department or group, build and dynamically adjust its own internal FSMP supply catalogue, verify product qualifications, and admit only FSMP registered by SAMR. The institution must set up rules for selection, review, procurement, use, periodic evaluation and exit, managing FSMP centrally and standardising the processes for receiving, using and charging.

2. In-hospital management systems. Institutions must take effective control measures across procurement, storage, sale and use; establish and refine systems for incoming-goods inspection and record-keeping (进货查验记录制度), warehouse management, in-and-out management, and handling of non-conforming FSMP; and designate personnel responsible for food-safety management. Practitioners involved in FSMP use — physicians or clinical nutritionists — should have clinical-nutrition education or training, plus FSMP-use knowledge and standardised-management training.

3. Clinical-use discipline. Practitioners should follow a standardised nutrition-diagnosis-and-treatment pathway, giving priority to dietary guidance and only proposing FSMP where dietary intervention cannot meet clinical needs and there are clinical indications. When recommending FSMP, they should explain the product’s details and its non-drug nature, whether alternative food or medicine exists, and obtain patient or family consent where used. FSMP use during a hospital stay should be recorded in the medical record, and the institution’s FSMP management department or group should evaluate the standardisation and reasonableness of use.

Selling and charging rules that matter commercially

Four operational rules are particularly important for producers and distributors:

  • Dedicated zone or counter. Institutions that sell FSMP must set up a separate sales area with a prominent sign reading “特殊医学用途配方食品销售专区(或专柜)”.
  • Record retention. Sales information — including patient information, FSMP name, specification and price — must be recorded and kept for a retention period consistent with medical records. This is a significant compliance consideration under the Personal Information Protection Law for patient-related data.
  • No prescriptions; separate billing. FSMP are not drugs, so they cannot be prescribed; their distribution and charging must be separated from pharmaceuticals. Institutions are encouraged to adopt information-system coding management that brings FSMP sales and use into hospital information systems.
  • No coercion. It is prohibited to sell or use, in the name of FSMP, any food that is not registered or that implies it can meet the special nutritional or dietary needs of the target populations. It is also prohibited to force or induce patients to buy FSMP in the institution or at designated outlets.

Recall co-operation

Institutions must co-operate with FSMP producers on recalls: once aware that a producer is recalling unsafe FSMP, the institution must immediately stop selling and seal the product and post a recall notice in a prominent position. Producers should therefore ensure their recall procedures reach hospital customers promptly and are documented.

What this means for producers and distributors

  • Registration is the admission ticket to the hospital channel. Hospitals may only list SAMR-registered FSMP in their supply catalogues. For importers, this reinforces the existing requirement to hold a Chinese registration for each product sold in China; products without registration cannot legally enter the hospital channel regardless of clinical demand.
  • The path to hospital formulary entry is now formal. Producers should expect hospital procurement to be run through the dedicated management group, with qualification review, and periodic re-evaluation. Building clinical-nutrition evidence and co-operation with nutrition departments — rather than prescription-oriented promotion — becomes the compliant route to market access.
  • Compliance burden moves down the chain. Distributors serving hospitals must ensure that labelling, storage and delivery meet the dedicated-zone and traceability expectations, and that patient-related sales data handling complies with privacy rules.
  • Regional variation is expected. The Opinions acknowledge that regions differ in economic development, medical-resource allocation and clinical-nutrition development, and encourage local implementation adapted to local conditions. Producers should track provincial implementation measures.
  • Opportunity in the nutritional-support gap. With an ageing population and growing awareness of clinical nutrition, FSMP remain a growth category; clearer rules that professionalise the hospital channel can favour compliant, well-evidenced brands — domestic and foreign alike.

Practical steps

  • Verify that every FSMP product marketed into China holds a valid SAMR registration matching the exact formula and label in use.
  • Prepare hospital-facing materials that support nutrition-department education and formulary review (clinical evidence summaries, usage guidance compliant with non-drug positioning).
  • Ensure recall plans include hospital customers and rapid notification mechanisms.
  • Review distributor agreements for compliance with dedicated-zone sale, record-retention and no-coercion rules.
  • Monitor provincial implementation guidance and adjust sales models per region.

Sources

  • 市场监管总局 — 国家卫生健康委办公厅 市场监管总局办公厅关于规范医疗机构特殊医学用途配方食品使用的指导意见(全文): https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/tssps/art/2026/art_81290de7385d4573939b6790103a5fb1.html
  • 市场监管总局(新闻)— 两部门联合出台指导意见 规范医疗机构使用特殊医学用途配方食品: https://www.samr.gov.cn:8007/xw/zj/art/2026/art_b34e6b283ecf4530a93aef63c6194e9f.html
  • 毕节市人民政府(政策解读转载)— 划红线、建目录、禁开处方!国家出台新规规范特医食品使用: https://www.bijie.gov.cn/bm/bjswsjkj/zwgk/zcwjjjd/202608/t20260831_90801118.html
  • 人民网湖北频道 — 国家卫生健康委等规范医疗机构特医食品使用管理: https://hb.people.com.cn/n2/2026/0831/c192237-41681914.html

Related reading

  • see also: China’s FSMP registration regime — the 2024 Administrative Measures baseline (fsmp-registration-measures)
  • see also: medical-device and pharma market entry routes into Chinese hospitals (healthcare-market-access)

特医食品医院渠道走向规范化:两部门出台医疗机构使用指导意见

概述

2026年8月下旬,国家卫生健康委办公厅与市场监管总局办公厅联合印发《关于规范医疗机构特殊医学用途配方食品使用的指导意见》(成文日期2026年8月6日,8月26日前后对外发布)。指导意见依据《食品安全法》《医疗机构管理条例》等法律法规制定,适用于各级各类医疗机构内特医食品的遴选、销售与使用,是国家层面首次为医院如何管理、采购、销售和使用特医食品建立完整操作框架。特医食品正处于食品、营养与临床照护的交叉地带,此前的管理长期存在模糊区。

什么是特医食品——以及为何需要专门规则

特医食品是指经国家市场监管部门注册可以在国内市场销售,为满足进食受限、消化吸收障碍、代谢紊乱或特定疾病状态人群对营养素或膳食的特殊需要,专门加工配制而成的配方食品。对这些人群的治疗、康复及机体功能维持起着重要营养支持作用。它看起来像医疗产品、法律上却是食品:注册环节适用食品法,实际使用却是临床行为,医院在采购、定价、储存与使用上长期缺乏统一规则。

指导意见重申根本边界:特医食品须在医师或临床营养技师指导下使用,且不属于药品。文件适用于持有《医疗机构执业许可证》或诊所备案凭证、依法从事疾病诊断和治疗活动的诊疗机构。

三层制度要求

一、治理架构。 医疗机构须确立特医食品使用管理部门或小组,建立并动态调整本机构《特殊医学用途配方食品供应目录》,审核产品资质,只允许经国家市场监管部门注册的特医食品进入目录。医院要建立遴选、审核、采购、使用、定期评估和退出制度,对特医食品集中统一管理,规范领取、使用与收费流程。

二、院内管理制度。 医院须在采购、贮存、销售及使用等环节采取有效控制措施,建立健全进货查验记录制度、仓储场所管理制度、出入库管理制度及不合格特医食品处置制度,明确负责食品安全管理的人员。从事特医食品使用工作的医师或临床营养技师等,应经过临床营养专业教育或培训,以及特医食品使用知识和规范化管理培训。

三、临床使用规范。 医师或临床营养技师应严格遵照规范化营养诊疗流程,优先提出膳食指导建议;膳食干预无法满足临床需求时,方可根据临床应用指征提出必要的特医食品使用建议。提出建议时应说明食品详情和非药品属性、是否有可替代的食品或药品,使用应征得患者或家属同意。患者住院期间使用特医食品的情况应记入病历,医院特医食品使用管理部门或小组应组织评估使用规范性与合理性。

对商业运营至关重要的销售与收费规则

以下四项操作性规则对生产企业和经销商尤其关键:

  • 专区专柜。 医疗机构经营特医食品,应设专门的销售区域,显著位置设提示牌,注明”特殊医学用途配方食品销售专区(或专柜)”字样。
  • 信息留存。 对销售信息(含患者信息、特医食品名称、规格、价格)进行记录和保存,保存时限参照病历。涉及患者信息的数据处理须同时符合《个人信息保护法》等要求。
  • 不得开处方、收费分离。 特医食品不属于药品、不得开具处方,其发放、收费等应当与药品区分;鼓励有条件的机构做好信息业务编码管理,将特医食品销售和使用项目纳入院内信息系统。
  • 禁止强制销售。 严禁以特医食品名义销售或使用未经国家注册批准、明示或暗示可用于满足目标人群特殊营养或膳食需要的食品;严禁强制或诱导患者在本机构或到指定地点购买。

召回配合

医疗机构应配合特医食品生产企业开展召回:一旦知悉企业召回不安全特医食品,应立即停止销售并封存、在醒目位置张贴召回公告。生产企业应确保召回程序能及时触达医院客户并留存记录。

对企业与经销商的意义

  • 注册资质是进入医院渠道的门票。 医院目录只接纳经国家注册的特医食品。进口商须为在华销售的每个产品持有有效中国注册证;无注册证的产品无论临床需求多大都无法合法进入医院渠道。
  • 进入院内目录的路径正式化。 生产企业应预期采购由专门管理小组按资质审核与定期再评估流程运作。建立临床营养证据、与营养科开展合规合作,而非”类处方”式促销,成为合规的市场准入路径。
  • 合规压力沿渠道下移。 服务医院的经销商须确保标签、储存与配送满足专区与可追溯预期,涉患者销售数据的处理符合隐私规则。
  • 地区差异可期。 指导意见承认各地在经济发展水平、医疗资源配置与临床营养学科建设上存在差异,鼓励各地结合本地实际实施。企业应跟踪省级落实细则。
  • 营养支持缺口中的机遇。 在人口老龄化与临床营养意识提升背景下,特医食品仍是增长品类;医院渠道专业化的清晰规则,将有利于合规、有证据的国内外品牌。

实务建议

  • 核验在华销售的每个特医食品产品均持有与在用配方、标签一致的有效的国家注册证。
  • 准备面向医院的合规材料,支持营养科教育与目录评审(临床证据摘要、符合非药品定位的使用指引)。
  • 确保召回计划覆盖医院客户并具备快速通知机制。
  • 审查经销商协议,确保其遵守专区销售、记录留存与禁止强制销售规则。
  • 跟踪各省级实施指引,分区域调整销售模式。

来源

  • 市场监管总局 — 国家卫生健康委办公厅 市场监管总局办公厅关于规范医疗机构特殊医学用途配方食品使用的指导意见(全文): https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/tssps/art/2026/art_81290de7385d4573939b6790103a5fb1.html
  • 市场监管总局(新闻)— 两部门联合出台指导意见 规范医疗机构使用特殊医学用途配方食品: https://www.samr.gov.cn:8007/xw/zj/art/2026/art_b34e6b283ecf4530a93aef63c6194e9f.html
  • 毕节市人民政府(政策解读转载)— 划红线、建目录、禁开处方!国家出台新规规范特医食品使用: https://www.bijie.gov.cn/bm/bjswsjkj/zwgk/zcwjjjd/202608/t20260831_90801118.html
  • 人民网湖北频道 — 国家卫生健康委等规范医疗机构特医食品使用管理: https://hb.people.com.cn/n2/2026/0831/c192237-41681914.html

相关阅读

  • 见:中国特医食品注册管理——《注册管理办法》(2024年施行)基线(fsmp-registration-measures)
  • 见:药品与医疗器械进入中国医院市场的路径(healthcare-market-access)

China’s one-year vehicle production-consistency and quality campaign: what it means for automakers and suppliers

  • On 27 August 2026, the Ministry of Industry and Information Technology (MIIT), the Ministry of Public Security, the Ministry of Ecology and Environment and SAMR jointly launched a one-year special campaign on production consistency and quality improvement for road motor vehicles (document MIIT Office letter 联通装函〔2026〕407号, dated 21 August 2026).
    2026年8月27日,工业和信息化部、公安部、生态环境部、市场监管总局四部门联合发布通知,自即日起在全国开展为期一年的道路机动车辆产品生产一致性和质量提升专项行动(文号:工信厅联通装函〔2026〕407号,落款日期2026年8月21日)。
  • The campaign targets four problem areas: production consistency (量产车参数与《公告》一致性), reliability, durability and test verification of new technologies, in an effort to steer the intensely price-competitive NEV market back towards quality and technology.
    专项行动集中整治四方面问题:生产一致性、可靠性、耐久性与新技术测试验证,意在把竞争激烈的新能源汽车市场引导回”质量与技术”赛道。
  • Production consistency checks cover three layers: whether mass-produced vehicles match the parameters and mandatory national standards in the vehicle Public Announcement; how OEMs manage component suppliers (procurement standards, incoming inspection, parts quality); and the OEM’s consistency-assurance capability (personnel, equipment, processes, management systems).
    生产一致性检查覆盖三个层面:量产车技术指标与《道路机动车辆生产企业及产品公告》参数及国家标准的一致性;整车企业对零部件供应商的管理(采购标准、进货检验、零部件质量);整车企业生产一致性保证能力(人员、设备、工艺、管理体系)。
  • Verification of new technologies now extends to intelligent-connected vehicles and AI: driving-assistance and autonomous-driving functions must be sufficiently tested and validated, product and cloud-platform data and network security protections must be adequate, and logs for incident investigation must be complete.
    新技术测试验证延伸到智能网联与人工智能:组合驾驶辅助及自动驾驶功能须充分测试验证,产品与云端平台的数据安全、网络安全防护须充分,用于案事件调查的日志留存须完整。
  • For foreign brands manufacturing in China and global suppliers to Chinese OEMs, the campaign signals stricter enforcement of the “公告准入—一致性保持—质量责任” chain and deeper scrutiny of the supply chain; quality consistency work that used to be paperwork-heavy now faces real verification against samples and test data.
    对在华生产的外资品牌与供应中国主机厂的全球零部件企业而言,专项行动意味着”公告准入—一致性保持—质量责任”链条执法收紧、供应链穿透式检查加深;过去偏重纸面材料的一致性工作将面临样车抽检与试验数据的实地核验。

China’s one-year vehicle production-consistency and quality campaign: what it means for automakers and suppliers | 四部门启动为期一年的机动车生产一致性与质量提升专项行动

Overview

On 27 August 2026, four Chinese authorities — the Ministry of Industry and Information Technology (MIIT), the Ministry of Public Security, the Ministry of Ecology and Environment and the State Administration for Market Regulation (SAMR) — jointly published the Notice on Launching a Special Campaign on Production Consistency and Quality Improvement for Road Motor Vehicles (关于开展道路机动车辆产品生产一致性和质量提升专项行动的通知, 工信厅联通装函〔2026〕407号). The campaign runs nationwide for one year from the date of issue and follows a 17 July 2026 meeting at which MIIT’s Equipment Industry Department I asked major automakers to strengthen self-inspection, and unannounced consistency inspections at OEMs including GAC Aion, Xpeng, Chery, NIO and JAC during July.

The campaign’s stated purpose is to regulate the competitive order of the new-energy-vehicle (NEV) industry and hold the line on production consistency and quality safety. Coming after a period of aggressive price competition in China’s NEV market, the initiative is widely read by analysts as a signal that competition must return to quality and technology rather than price and speed.

The four problem areas under scrutiny

1. Production consistency (生产一致性). This is the first and deepest target. Inspections verify:

  • whether mass-produced vehicles’ technical parameters match the vehicle Public Announcement (《公告》) and comply with relevant mandatory national standards;
  • how the OEM manages component suppliers — procurement standards, incoming inspection and parts-quality management;
  • whether the OEM has a genuine consistency-assurance capability: personnel competence, production and inspection equipment, purchased raw materials and parts assemblies and their suppliers, production processes, working environment and management systems.

MIIT’s Equipment Industry Development Centre describes production consistency as the baseline institutional requirement of vehicle admission management: the parameters, configurations and performance of batch-produced vehicles must remain consistent with the type-approved product, the type-test sample and the certificate information, and continue to meet mandatory national standards. On 28 August 2026, MIIT published typical cases from the 2025 NEV production-consistency supervision and inspection, including sample vehicles delivered without user manuals, individual parameters inconsistent with the Announcement, and emergency-window net areas and side/rear underrun-protection performance failing national-standard requirements.

2. Reliability (可靠性). Checks cover the reliability testing and validation of complete vehicles, key systems and components, and whether manufacturing processes and standards at OEMs and parts makers can guarantee reliability.

3. Durability (耐久性). Inspectors look at new-vehicle design service life and R&D cycles, body-material selection, anti-corrosion processes and structural protection, and recorded problems such as defects, corrosion and suspension fractures.

4. Test verification of new technologies (新技术测试验证). This category is squarely aimed at the intelligent-connected era:

  • whether innovative designs adequately assess risks to user habits, misuse and extreme-use scenarios, and whether marketing claims match reality;
  • whether new materials and structures carry hidden defect or fatigue-failure risks;
  • whether combined driving-assistance and autonomous-driving functions have been sufficiently tested and validated; whether product and cloud-platform data-security and network-security protections are adequate; whether AI-safety protections are adequate; whether security measures were planned, built and put into use simultaneously (“三同步”); and whether logs needed for incident investigation are complete.

The campaign also calls for establishing industry-wide third-party testing and evaluation activity guidelines that are standardised, open, fair and traceable, continued crackdowns on exaggerated and false advertising, and public disclosure of problem enterprises and inspection bodies to draw clear “red lines”.

How the campaign is enforced

The Notice asks provincial industry-and-information-technology, public-security, ecology-and-environment and market-regulation departments to implement it in their localities under territorial responsibility, strictly regulate administrative inspections of enterprises, and report results to the four ministries after the year ends. An annex sets out a work plan for inspecting manufacturers’ product-safety-assurance capability and production consistency.

Key expectations are placed on:

  • Vehicle manufacturers: strengthen their primary responsibility for production consistency and quality safety, conduct deep self-inspection and correction, resist irrational competition, tighten supply-chain management, strengthen consistency-assurance capability, improve testing and validation of new products, standardise marketing claims, and hold the product-safety line.
  • Inspection and testing institutions: operate lawfully, impartially and objectively, and genuinely improve work quality.
  • Industry associations: guide self-discipline and corporate social responsibility.
  • Standardisation bodies: accelerate the drafting and revision of relevant standards.
  • Technical-service institutions: strictly conduct technical review, including assessment of innovative designs.

What this means for foreign-invested players

  • Localised manufacturers under sharper scrutiny. Foreign brands producing NEVs in China — whether through wholly owned plants or joint ventures — must verify that mass-production data, supplier records and certification documents align with the Announcement for every model sold. Discrepancies that previously triggered warnings may now produce public naming and penalties.
  • Suppliers drawn into the inspection web. Because consistency checks reach into procurement standards and incoming inspection, component suppliers (batteries, motors, electronics, chassis) will face more demanding customer audits and possibly direct regulatory contact. Global suppliers should expect OEM requests for higher documentation standards and tighter quality agreements.
  • The intelligent-driving agenda is now a compliance topic. With AI and autonomous-driving functions inside the test-verification scope, software-defined vehicle makers and their algorithm/data partners must demonstrate adequate testing, cybersecurity and data-protection measures, and complete log retention. This aligns with the mandatory national standards for intelligent-connected vehicles (e.g. GB 44721—2026 and GB 47955—2026, published 2026) that set a framework for safe operation of the technology.
  • Marketing claims need a legal scrub. The campaign’s emphasis on curbing exaggerated and false advertising means sales and PR materials making performance, range or safety claims should be reviewed against verified test data.

Practical steps

  • Run an internal consistency audit: compare current production configuration, software versions and component part numbers against the Announcement and certification files for each model.
  • Tighten supplier quality management: verify incoming-inspection records, and ask key suppliers to confirm their own consistency controls.
  • Strengthen test-verification documentation for ADAS/AD features, including cybersecurity reviews of vehicle and cloud platforms and log-retention arrangements.
  • Prepare for potential on-site inspection and sample testing; designate a responsible officer for campaign-related queries from local authorities.
  • Review advertising and marketing materials for consistency with verified technical data before publication.

Sources

  • 工信部装备工业发展中心 — 工业和信息化部等四部门办公厅关于开展道路机动车辆产品生产一致性和质量提升专项行动的通知(全文): https://www.miit-eidc.org.cn/art/2026/8/27/art_1657_12693.html
  • 工信微报(网易转载)— 四部门联合整治汽车质量 推动行业竞争回归质量与技术: https://www.163.com/dy/article/L5IO290I0514K35E.html
  • 央视新闻(今日头条转载)— 四部门开展专项行动集中整治车辆可靠性耐久性等问题: https://www.toutiao.com/article/7678641260592103986

Related reading

  • see also: NEV 15th Five-Year Plan signals — where the sector is heading (341-nev-fifteenth-fyp)
  • see also: China’s mandatory national standards for intelligent-connected vehicles (intelligent-connected-vehicle-gb-standards)

四部门启动为期一年的机动车生产一致性与质量提升专项行动

概述

2026年8月27日,工业和信息化部、公安部、生态环境部、市场监管总局联合发布《关于开展道路机动车辆产品生产一致性和质量提升专项行动的通知》(工信厅联通装函〔2026〕407号,落款日期2026年8月21日),宣布自即日起在全国范围内开展为期一年的专项行动。此前的7月17日,工信部装备工业一司已召开重点汽车生产企业座谈会部署自查;7月下旬又对广汽埃安、小鹏、奇瑞、蔚来、江淮等企业开展产品安全保障能力和生产一致性监督检查。

专项行动旨在规范新能源汽车产业竞争秩序、守牢产品生产一致性和质量安全底线。在经历一轮激烈价格战之后,业内普遍将其解读为:竞争必须回到质量与技术,而不是价格与速度。

重点整治的四个方面

一、生产一致性。 这是排在第一位的深度整治对象,检查涵盖三方面:

  • 整车企业量产车技术指标与《道路机动车辆生产企业及产品公告》参数的一致性、相关国家标准的符合性;
  • 整车企业对零部件供应商的管理情况——采购标准、进货检验、零部件产品质量管理;
  • 整车企业的生产一致性保证能力——人员能力、生产与检验设备、采购的原材料和零部件总成及其供应商、生产工艺、工作环境、管理体系。

工信部装备工业发展中心将生产一致性概括为机动车准入管理的基础制度要求:企业批量生产销售车辆的技术参数、配置、性能,要与《公告》型式批准的产品、型式试验样品、合格证信息保持一致,持续符合国家强制性标准。8月28日,工信部公开曝光2025年度新能源汽车产品生产一致性监督检查典型案例,包括样车未配说明书、个别参数与《公告》不一致、应急窗净面积与侧后防护装置性能不符合国标要求等。

二、可靠性。 检查整车产品、关键系统和零部件的可靠性测试验证情况,以及整车与零部件企业生产制造工艺标准能否保证产品可靠性。

三、耐久性。 检查整车企业新车设计使用寿命和研发周期、车身材料选用、防腐工艺、结构防护要求,以及产品缺陷、锈蚀、悬架断裂等问题。

四、新技术测试验证。 这一项直接指向智能网联时代:

  • 新产品创新设计对用户习惯、误操作风险、极端使用场景的风险评估是否充分,营销宣传是否符合实际;
  • 新材料、新结构是否存在产品缺陷、疲劳失效等风险隐患;
  • 组合驾驶辅助及自动驾驶功能测试验证是否充分;产品及云端平台数据安全、网络安全防护是否充分;人工智能安全防护是否充分;是否同步规划、同步建设、同步使用;用于案事件调查的日志留存是否完整。

专项行动还要求研究建立规范、公开、公正、可追溯的汽车行业第三方测评活动指南,持续整治汽车行业网络乱象、严厉打击夸大和虚假宣传,公开通报问题企业与检验机构,为行业划清”红线”、守牢”底线”。

如何执行

通知要求各地工信、公安、生态环境、市场监管部门落实属地责任,开展本地区专项行动,严格规范涉企行政检查,一年期满后向四部门报送工作情况。附件为《道路机动车辆生产企业产品安全保障能力和生产一致性监督检查工作方案》。

各环节责任被明确压实:整车企业要深入开展自查自纠、自觉抵制非理性竞争、加强供应链管理、强化生产一致性保证能力、加强新产品测试验证、规范营销宣传;检验检测机构要依法依规公正客观执业;行业协会引导自律;标准化组织加快标准制修订;技术服务机构严格技术审查并加强对创新设计的审查评估。

对外资车企与供应商的意义

  • 本土化生产的外资品牌面临更严核验。 无论独资还是合资,外资新能源品牌必须确保每个在售车型的量产数据、供应商记录与认证文件同《公告》一致。以往可能只是警示的偏差,如今可能被公开点名并处罚。
  • 供应商被纳入穿透式检查网。 一致性检查深入采购标准与进货检验,电池、电机、电控、底盘等零部件供应商将面对更严苛的客户审核,甚至监管部门的直接接触。全球供应商应预期主机厂提出更高的文件化标准和更严的质量协议。
  • 智能驾驶议题成为合规议题。 自动驾驶与人工智能功能进入测试验证范围,软件定义汽车厂商及其算法、数据合作伙伴必须证明测试充分、网安与数据保护到位、日志留存完整。这与2026年发布的多项智能网联汽车强制性国家标准(如GB 44721—2026、GB 47955—2026)相衔接,共同为技术安全运行划定框架。
  • 营销话术需要法务审查。 专项行动强调遏制夸大与虚假宣传,销售与公关材料中的性能、续航、安全类表述应与经核验的试验数据一致。

实务建议

  • 开展内部一致性审计:逐车型核对量产配置、软件版本与零部件号是否与《公告》和认证文件一致。
  • 收紧供应商质量管理:核查进货检验记录,要求关键供应商确认其自身一致性管控。
  • 完善ADAS/AD功能测试验证文档,包括车端与云端平台的网络安全审查与日志留存安排。
  • 为可能的现场检查与样车抽检做准备,指定专人对接地方主管部门在行动期间的问询。
  • 发布前审查广告与营销材料的各项表述是否与已核验技术数据一致。

来源

  • 工信部装备工业发展中心 — 四部门办公厅关于开展道路机动车辆产品生产一致性和质量提升专项行动的通知(全文): https://www.miit-eidc.org.cn/art/2026/8/27/art_1657_12693.html
  • 工信微报(网易转载)— 四部门联合整治汽车质量 推动行业竞争回归质量与技术: https://www.163.com/dy/article/L5IO290I0514K35E.html
  • 央视新闻(今日头条转载)— 四部门开展专项行动集中整治车辆可靠性耐久性等问题: https://www.toutiao.com/article/7678641260592103986

相关阅读

  • 见:新能源汽车”十五五”政策信号——产业走向何方(341-nev-fifteenth-fyp)
  • 见:中国智能网联汽车强制性国家标准(intelligent-connected-vehicle-gb-standards)

Fujian’s “15th Five-Year Plan” education blueprint opens the door wider for Sino-foreign cooperative education

  • On 24 August 2026, the Fujian provincial government printed and distributed the Fujian “15th Five-Year Plan” Education Development Plan (闽政〔2026〕24号), setting the 2030 goal that a strong-education-province foundation is further consolidated and a high-quality education system is basically completed.
    2026年8月24日,福建省人民政府印发《福建省”十五五”教育发展规划》(闽政〔2026〕24号),提出到2030年教育强省建设基础进一步夯实、高质量教育体系基本建成的目标。
  • The Plan explicitly supports localities and universities in introducing world-renowned universities to run Sino-foreign cooperative education institutions and programmes in Fujian, focusing on urgently needed, science-engineering-agriculture-medicine and cross-disciplinary frontier subjects, and supports Tianjin University’s Fuzhou International Joint College in establishing further cooperative institutions and programmes.
    规划明确”鼓励境外高水平大学来闽设立中外合作办学机构和项目”,支持各地和高校引进世界知名大学,聚焦急需紧缺、理工农医、交叉前沿学科举办中外合作办学机构和项目;支持天津大学福州国际联合学院设立若干中外合作办学机构和项目。
  • A dedicated “Sino-Foreign Cooperative Education Support Plan” is listed as a major project in the Plan’s special column on cross-strait education integration and high-level opening-up, alongside the “Future Maritime Silk Road Excellent Partners” plan and an “International Chinese Education Leading” plan.
    规划在”推动闽台教育融合发展和教育高水平开放合作重大工程”专栏单列”中外合作办学支持计划”,与”未来海丝卓越伙伴”计划、”国际中文教育领航”计划并列。
  • For Hong Kong and Macao institutions, the Plan promises support for high-quality higher-education resources from Hong Kong and Macao to land in Fujian and for joint talent-training programmes between Fujian and Hong Kong/Macao universities.
    对港澳高校,规划提出”支持港澳优质高等教育资源落地福建,推进闽港澳高校人才联合培养项目”,并常态化开展闽港澳中小学姊妹校交流。
  • For foreign universities and education investors, the Plan is a concrete provincial invitation: Fujian pairs its manufacturing and maritime economy with international higher education, opening a window for brand-name universities to enter through Fuzhou, Xiamen and the Pingtan experimental zone under China’s existing Sino-foreign cooperative education regulatory framework.
    对外国大学与教育投资者而言,这是一份具体的省级邀请函:福建把制造业与海洋经济同国际高等教育对接,为知名大学在中国现有中外合作办学监管框架下经福州、厦门及平潭试验区进入提供了窗口。

Fujian’s “15th Five-Year Plan” education blueprint opens the door wider for Sino-foreign cooperative education | 福建”十五五”教育规划:中外合作办学的大门开得更宽

Overview

On 24 August 2026, the Fujian provincial government printed and distributed the Fujian “15th Five-Year Plan” Education Development Plan (《福建省”十五五”教育发展规划》, 闽政〔2026〕24号). Drafted under the national Education Development “15th Five-Year Plan” and Fujian’s own 15th Five-Year economic-and-social plan, the document sets the 2030 goal that the foundation for building Fujian into a strong education province is further consolidated and a high-quality education system is basically completed. For international education providers, the parts that matter most sit in the sections on deepening cross-strait education integration and raising the level of international opening-up in education.

Development goals for 2030

The Plan sets out targets including: pre-school three-year enrolment maintained above 99.5 per cent and public-kindergarten share above 65 per cent; nine-year compulsory-education consolidation kept above 99 per cent; and an explicit ambition that the level of Sino-foreign cooperative education rises markedly and Fujian’s education influence continues to expand. Higher education is expected to restructure its types, levels and layout, with discipline structures increasingly matched to the province’s modern industrial clusters and future industries — the context in which international partners are invited in.

The four tracks of education opening-up

The Plan organises Fujian’s international education agenda under four major projects in a special column on “Promoting the Integrated Development of Fujian-Taiwan Education and High-Level Opening-up of Education”:

1. Fujian-Taiwan education integration project (闽台教育融合发展工程). Universities are supported in recruiting students from Taiwan through multiple channels; single-recruitment for Taiwan students is to be expanded to all public undergraduate universities and quality higher-vocational colleges; high-quality Taiwan higher-education resources are to be introduced for cooperative education in Fujian; and Fujian-Taiwan characteristic discipline clusters and high-level research and innovation platforms are to be co-built.

2. Sino-foreign cooperative education support plan (中外合作办学支持计划). The Plan supports localities and universities in introducing world-renowned universities to establish Sino-foreign cooperative education institutions and programmes in Fujian, concentrating on disciplines that are urgently needed, aligned with national strategy and regional development, spanning science, engineering, agriculture and medicine, and at the frontier of cross-disciplinary fields. It also supports Tianjin University Fuzhou International Joint College in establishing a number of cooperative education institutions and programmes. The existing college — a milestone project between Tianjin University and the city of Fuzhou — is treated as a platform to be scaled rather than a one-off.

3. “Future Maritime Silk Road Excellent Partners” plan (未来海丝卓越伙伴计划). Fujian will keep building the “21st Century Maritime Silk Road” university alliance, improve the Chinese-foreign dual-supervisor talent-cultivation mechanism, advance international industry-university-research co-operation, deepen the “Study in Fujian — Excellent International Summer School” programme, and expand exchanges with universities, research institutes and enterprises in friendly provinces, states and sister cities.

4. “International Chinese Education Leading” plan (国际中文教育领航计划). Fujian will strengthen its international Chinese education and study-in-China alliances, support universities in building smart Chinese-learning platforms and localised teaching resources, promote the transformation of Confucius Institutes towards “language services + professional domains”, and co-ordinate international Chinese education with overseas Chinese-language education.

Alongside these four projects, the Plan separately commits to bringing Hong Kong and Macao into the picture: “support high-quality higher-education resources from Hong Kong and Macao to land in Fujian, advance Fujian-Hong Kong/Macao joint talent-training projects at universities”, expand teacher visits to Hong Kong and Macao for study and research, and routinise sister-school exchanges between Fujian and Hong Kong/Macao primary and secondary schools.

Regulatory context for foreign entrants

Sino-foreign cooperative education in China operates under the Regulations on Sino-Foreign Cooperative Education (2003) and its implementation rules, administered by the Ministry of Education at the national level for institution-establishment, with programme-level approvals also handled by provincial education departments within delegated authority. Fujian’s Plan does not change the national framework; it signals provincial demand and prioritisation — a necessary ingredient for a successful application, since provincial recommendation and support materially smooth the approval process. The Tianjin University Fuzhou International Joint College precedent shows the “famous Chinese university + overseas partner” or “Chinese university-led, overseas partner-in” model that the province prefers to scale.

What this means for foreign universities and investors

  • A provincial-level demand signal. Provinces compete to attract top international education brands; Fujian has now written Sino-foreign cooperative education expansion into its statutory five-year plan, with an explicit support plan and named platform (Tianjin University Fuzhou International Joint College). Foreign universities evaluating a China campus should treat Fujian as an actively recruiting destination.
  • Discipline focus is defined. Needed fields are “urgently needed, aligned with national strategy and regional development, science-engineering-agriculture-medicine and cross-disciplinary frontier”. Maritime, new-energy, digital-economy, healthcare and advanced-manufacturing-linked programmes are natural fits given Fujian’s industrial base.
  • The “university-led” platform model is favoured. Rather than brand-new greenfield campuses alone, the province favours established Chinese universities (e.g. Tianjin University in Fuzhou) adding overseas partners and programmes — a lower-risk entry model for foreign institutions than sole establishment.
  • Hong Kong and Macao universities have a fast lane. The explicit commitment to Hong Kong/Macao higher-education resources and joint programmes reflects the Greater Bay Area-style deepening of cross-border education co-operation and gives Hong Kong and Macao institutions a clearly articulated provincial invitation.
  • Taiwan-channel caution. Foreign institutions should be mindful that Fujian’s Taiwan-facing education agenda operates within the relevant cross-strait arrangements; for non-Chinese universities, the main practical relevance is the province’s overall openness posture and its competition for international partners.

Practical steps

  • For universities considering a China campus: engage the Fujian provincial education department early to test feasibility, and review the Tianjin University Fuzhou International Joint College model as a template.
  • Identify a Chinese university partner with complementary strengths; Sino-foreign cooperative education institutions require a Chinese partner institution by regulation.
  • Align proposed disciplines with Fujian’s industrial clusters (maritime economy, advanced manufacturing, digital economy, healthcare) to strengthen the provincial-support case.
  • For programme-level entry, confirm whether the intended programme requires Ministry of Education or provincial approval and prepare the feasibility, curriculum, faculty and quality-assurance documents accordingly.
  • Monitor Fujian’s implementation measures and any provincial catalogue or application guidance that follows the Plan during late 2026.

Sources

  • 福建省人民政府 — 关于印发《福建省”十五五”教育发展规划》的通知(闽政〔2026〕24号,全文): https://www.fujian.gov.cn/zwgk/zxwj/szfwj/202608/t20260828_7206084.htm
  • 福建省人民政府 — 《福建省”十五五”教育发展规划》政策解读: https://fujian.gov.cn/jdhy/zcjd/202608/t20260828_7206086.htm
  • 福州新闻网 — 福建印发”十五五”教育发展规划 到2030年普高招生计划比例力争达八成: https://news.fznews.com.cn/dsxw/20260830/6a9384b95dc47.shtml

Related reading

  • see also: how foreign universities enter China — Sino-foreign cooperative education pathways (sino-foreign-cooperative-education-pathways)
  • see also: Hainan’s international education island experiment (356-hainan-international-education)

福建”十五五”教育规划:中外合作办学的大门开得更宽

概述

2026年8月24日,福建省人民政府印发《福建省”十五五”教育发展规划》(闽政〔2026〕24号)。规划依据国家《教育发展”十五五”规划》与《福建省国民经济和社会发展第十五个五年规划纲要》制定,提出到2030年教育强省建设基础进一步夯实、高质量教育体系基本建成的目标。对国际教育机构而言,最值得关注的内容集中在”深化闽台教育融合发展、提升国际教育开放合作水平”部分。

2030年发展目标

规划提出的目标包括:学前三年入园率保持在99.5%以上、公办园在园幼儿占比达到65%以上;九年义务教育巩固率保持在99%以上;并明确提出中外合作办学层次明显提升、福建教育影响力持续扩大。高等教育要在类型、层次、布局上持续优化,学科专业结构与全省现代化产业集群和未来产业体系更加适配——这正是邀请国际伙伴进入的背景。

教育对外开放的四条跑道

规划在”推动闽台教育融合发展和教育高水平开放合作重大工程”专栏下,用四个重大工程组织福建的国际教育议程:

一、闽台教育融合发展工程。 支持高校多渠道开展对台招生,推动对台单招扩大至全省公办本科高校及优质高职院校;引进台湾优质高等教育资源来闽合作办学,共建闽台特色专业群和高水平科研创新平台。

二、中外合作办学支持计划。 规划”支持各地和高校引进世界知名大学,聚焦符合国家战略和区域发展的急需紧缺、理工农医、交叉前沿的学科专业,来闽举办中外合作办学机构和项目”,并”支持天津大学福州国际联合学院设立若干中外合作办学机构和项目”。这所天津大学与福州市共建的标志性学院被当作可放大的平台,而非一次性项目。

三、”未来海丝卓越伙伴”计划。 持续建设”21世纪海上丝绸之路”大学联盟,完善中外双导师育人机制,推进国际产学研用合作,深入实施”留学福建—卓越国际暑校”项目,深化与友好省州友城所在国高校、科研院所和企业的交流合作。

四、”国际中文教育领航”计划。 加强”福建省国际中文教育暨来华留学联盟”等建设,支持高校打造中文智慧学习平台、开发本土化教学资源,推动孔子学院向”语言服务+专业领域”高质量发展,推动国际中文教育与海外华文教育协同发展。

在这四个项目之外,规划把港澳单独写入:“支持港澳优质高等教育资源落地福建,推进闽港澳高校人才联合培养项目”,加大骨干教师赴港澳访学研修选派力度,常态化开展闽港澳中小学姊妹校交流。

外资进入的监管背景

中国的中外合作办学适用《中外合作办学条例》(2003年)及其实施办法:设立机构由教育部在国家层面审批,项目层面在授权范围内也由省级教育部门办理。福建规划不改变国家框架,它释放的是省级需求与优先级信号——这是申请成功的关键要素之一,因为省级推荐与支持能实质性地畅通审批流程。天津大学福州国际联合学院的先例说明,福建偏好放大”国内名校牵头、海外伙伴加入”的模式。

对外国大学与投资者的意义

  • 省级需求信号明确。 各省都在争抢顶级国际教育品牌;福建已把扩大中外合作办学写入法定五年规划,并配以专门支持计划和具名平台(天津大学福州国际联合学院)。评估中国校区的海外大学,应把福建视为积极招引的目的地。
  • 学科方向已划定。 急需紧缺、服务国家战略与区域发展、理工农医、交叉前沿是关键词。结合福建产业基础,海洋、新能源、数字经济、医疗健康与先进制造相关专业天然契合。
  • 偏好”名校牵头”平台模式。 相比纯新建校园,福建更青睐既有国内高校(如福州的天大联合学院)叠加海外伙伴与项目——对外国院校而言,这是比独立设校风险更低的进入模式。
  • 港澳高校有快车道。 对港澳高等教育资源与联合培养项目的明确承诺,呼应大湾区式跨境教育合作深化,为港澳院校提供了清晰的省级邀请。
  • 涉台渠道需注意边界。 外国机构应注意,福建对台教育议程在相关两岸安排框架内运作;对非中国大学而言,主要实际意义在于福建整体开放姿态及其对国际伙伴的竞争。

实务建议

  • 考虑在华设校的大学:尽早对接福建省教育厅测试可行性,研究天津大学福州国际联合学院模式作为模板。
  • 寻找学科互补的中国合作高校——依条例中外合作办学机构必须有中国合作方。
  • 使拟设学科对接福建产业集群(海洋经济、先进制造、数字经济、医疗健康),以强化省级支持论证。
  • 项目级进入时,确认拟办项目需教育部还是省级审批,并据此准备可行性、课程、师资与质量保障材料。
  • 跟踪福建实施办法及2026年下半年规划后续出台的省级目录或申报指引。

来源

  • 福建省人民政府 — 关于印发《福建省”十五五”教育发展规划》的通知(闽政〔2026〕24号,全文): https://www.fujian.gov.cn/zwgk/zxwj/szfwj/202608/t20260828_7206084.htm
  • 福建省人民政府 — 《福建省”十五五”教育发展规划》政策解读: https://fujian.gov.cn/jdhy/zcjd/202608/t20260828_7206086.htm
  • 福州新闻网 — 福建印发”十五五”教育发展规划 到2030年普高招生计划比例力争达八成: https://news.fznews.com.cn/dsxw/20260830/6a9384b95dc47.shtml

相关阅读

  • 见:外国大学如何进入中国——中外合作办学路径(sino-foreign-cooperative-education-pathways)
  • 见:海南国际教育创新岛试验(356-hainan-international-education)

China’s drug traceability rules harden: full coding, full scanning from NMPA Announcement No. 85 of 2026

  • On 1 September 2026, the National Medical Products Administration (NMPA) published Announcement No. 85 of 2026 on Further Strengthening the Administration of Drug Information Traceability (dated 31 August 2026), demanding full-variety coding (“应赋尽赋”) and full-chain scanning (“见码必扫”).
    2026年9月1日,国家药监局发布《关于进一步加强药品信息化追溯管理工作的公告》(2026年第85号,落款2026年8月31日),提出”全品种赋码、应赋尽赋,全链条扫码、见码必扫”的总要求。
  • The announcement hardens legal duties across the whole chain — marketing-authorisation holders (MAHs), domestic agents of overseas MAHs, manufacturers, distributors, medical institutions and traceability-system operators — and, with limited exceptions (active pharmaceutical ingredients, medical oxygen, hospital preparations), all finished dosage forms in production must be coded; TCM decoction pieces follow separate rules.
    公告压实持有人、境外持有人指定境内责任人、生产企业、经营企业、使用单位及追溯系统运营单位等各方责任;除原料药、医用氧、医疗机构制剂等少数品类外,全部在产制剂品种均须赋码(中药饮片追溯要求另行制定)。
  • Code registration is tightened: MAHs and domestic agents must file drug identifier codes on the national co-ordination platform through the NMPA government-service portal and link identifier code, commodity bar code, national drug code and medical-insurance code; issuing bodies and system operators must also file to guarantee uniqueness.
    追溯码备案趋严:持有人、境内责任人须通过国家药监局政务服务门户登录国家药品追溯协同服务平台,及时准确完整备案药品标识码,完成标识码、商品条码、本位码、医保编码等多码关联;发码机构与系统运营单位须向平台备案以确保唯一性。
  • Distributors and end-users face hard scanning rules: wholesalers must treat code verification as a mandatory part of inbound acceptance and upload information on outbound review; pharmacies and medical institutions must verify codes on inbound acceptance, upload sales records, and refuse goods whose traceability shows they were already sold at another retail outlet; abnormal alerts require stopping sales pending quality-manager review.
    经营使用环节扫码成为硬性流程:批发企业须把扫码核对作为入库验收的必须内容并在出库复核时上传信息;零售药店与医疗机构入库验收须核对追溯码、销售时上传销售信息;发现追溯信息显示药品已在其他零售或使用单位售出的应拒收;出现异常预警应立即停止入库和销售,由质量负责人审核签字后处理。
  • For pharmaceutical companies importing into China and their local partners, the message is that traceability has moved from infrastructure-building to routine enforcement: performance will be woven into daily inspections by provincial drug administrations, with tampering or fabrication of traceability data punished under the Drug Administration Law and GSP-related rules.
    对进口药品企业与本地合作伙伴而言,信号明确:药品追溯已从”建基础设施”进入”常态化监管执法”阶段——省级药监部门将把追溯落实情况纳入日常检查,篡改、伪造追溯数据或不落实追溯义务者将依《药品管理法》《药品经营和使用质量监督管理办法》等严肃处理。

China’s drug traceability rules harden: full coding, full scanning from NMPA Announcement No. 85 of 2026 | 药品追溯进入”全品种全链条”强监管:国家药监局2026年第85号公告解读

Overview

On 1 September 2026, the National Medical Products Administration (NMPA) published Announcement No. 85 of 2026 on Further Strengthening the Administration of Drug Information Traceability (《国家药监局关于进一步加强药品信息化追溯管理工作的公告(2026年第85号)》), dated 31 August 2026. Building on the Drug Administration Law and its implementing regulations, the announcement consolidates years of pilot infrastructure into a compulsory, enforceable regime: every product coded, every code scanned, and every link answerable. NMPA officials described the drug traceability code as each pack’s “electronic identity card”, capable of recording where a product has been approved and how it moved through production and distribution.

The core principle: 应赋尽赋, 见码必扫

The announcement states the overall requirement as “full-variety coding — everything that should be coded must be coded; full-chain scanning — every code that appears must be scanned”. The coverage is nearly universal: with the exceptions of active pharmaceutical ingredients, medical oxygen and hospital preparations, all finished dosage forms in production fall within the traceability scope. Traditional Chinese medicine decoction pieces are governed by separate rules to be issued. This means imported finished drugs distributed in China are squarely within the regime, and their MAHs and domestic agents carry the first-layer obligations.

Duties by link in the chain

MAHs and domestic agents of overseas MAHs (持有人、境内责任人). They must:

  • file drug identifier codes through the NMPA government-service portal on the national drug traceability co-ordination platform, accurately and completely, linking the identifier code, commodity bar code, national drug code (本位码) and medical-insurance code;
  • follow the “one object one code, code and object tracked together” (一物一码、物码同追) principle, completing traceability-code activation before market launch, linking codes across all levels of sales packaging, and uploading traceability information accurately and promptly;
  • save in-warehouse records in the traceability system at finished-goods receipt, provide downstream traceability information at outbound sale, and promptly handle abnormal-code feedback from downstream parties so that information remains truthful and credible.

Manufacturers (生产企业). Alongside MAHs, they are responsible for coding activation and packaging-linkage before products are placed on sale, and for accurate, timely uploads.

Wholesale distributors (批发企业). Inbound acceptance must include obtaining traceability information from the upstream party and verifying the traceability code as a mandatory part of acceptance; they must feed receipt information back upstream and, at outbound-sale review, provide traceability information to downstream enterprises or medical institutions through the system.

Retail pharmacies and medical institutions (零售药店、医疗机构). On inbound acceptance they must verify codes against the upstream party and feed receipt information back; when selling, they must keep detailed sales records and upload sales information through the traceability system in a timely manner. Sales receipts must display the traceability code or offer another convenient query channel for consumers. Where the system raises an abnormal alert, the pharmacy or institution must immediately stop inbound acceptance and sales, verify and handle the alert, with the measures signed off by the quality manager and records kept per GSP requirements. Where inbound acceptance reveals traceability information showing the drug was already sold at a retail pharmacy or medical institution, the goods must be refused.

Traceability-system operators (追溯系统运营单位). They must maintain public-interest orientation, guarantee data security, provide recall support for MAHs and domestic agents, offer real-time early warning of abnormal traceability signals at inbound acceptance for wholesale, retail and user units, protect personal privacy and trade secrets in traceability data, and not disclose or illegally provide data to others. They must file with the national platform to ensure code uniqueness.

Supervision and enforcement

The announcement asks provincial drug administrations to make traceability performance part of daily inspection of enterprises and units in their regions, pushing full-variety coding activation and full-chain scanning and uploading (“应赋尽赋、应扫尽扫”). Entities that fail to comply with the regulations or with traceability requirements are to be handled seriously under the Drug Administration Law, the Measures for the Supervision and Administration of Drug Operation and Use, and the Good Supply Practice (GSP) rules. NMPA also stresses “三医协同” — co-ordination among the drug, medical-insurance and health authorities — and the use of traceability data for smart supervision, risk discovery and rapid handling. The data-security angle is explicit: system operators must build data-security management institutions under the Data Security Law and keep private and commercial data confidential.

Why this matters to foreign pharmaceutical companies

  • Traceability compliance is now an enforcement matter, not a project. Foreign MAHs importing finished drugs must ensure their domestic agent (境内责任人) operates the full coding-and-uploading cycle on the national platform. The agent is a regulated extension of the MAH; a weak agent means personal exposure for the MAH’s China compliance posture.
  • Multi-code linkage affects packaging and IT work. Linking the identifier code, commodity bar code, national drug code and medical-insurance code means packaging data and enterprise resource systems must be reconciled with Chinese regulatory identifiers before first import. Imported products already carrying GS1 codes still need the Chinese identifier-code linkage.
  • Channel discipline improves for compliant players. The rule that goods already sold elsewhere must be refused, and that abnormal alerts stop sales, directly attacks “reflux drugs” (回流药) and code-swapping fraud — problems that undercut legitimate pricing. Compliant importers benefit as grey channels close.
  • GSP-grade documentation is required across the distributor network. Distributors’ inbound/outbound scanning and the quality-manager sign-off on abnormal alerts become audit evidence; foreign firms should verify their Chinese distributors’ systems actually generate this documentation.
  • Co-ordination with medical-insurance settlement. NMPA links traceability to medical-insurance code-based settlement; announcements and practice increasingly tie code verification to reimbursement and anti-fraud work, so products without sound traceability data may face friction in hospital and insurance-channel reimbursement.

Practical steps

  • Confirm that the domestic agent of each imported MAH has an up-to-date registration on the national traceability co-ordination platform with correct multi-code linkage for every marketed SKU.
  • Audit packaging and labelling projects to ensure traceability codes, bar codes and hierarchy linkage are complete before first shipment into China.
  • Review distributor contracts to require GSP-compliant inbound/outbound scanning, abnormal-alert handling and quality-manager sign-off records.
  • Align internal ERP/quality systems with the platform’s data-upload requirements, including timely handling of downstream abnormal-code feedback.
  • Monitor provincial enforcement and any TCM-decoction-piece traceability rules still to be issued, and track the interaction between traceability and medical-insurance settlement in tender and hospital channels.

Sources

  • 国家药监局 — 国家药监局关于进一步加强药品信息化追溯管理工作的公告(2026年第85号): https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260901134430105.html
  • 医药网 — 药品追溯新规出台 压实全产业链主体监管责任: https://news.pharmnet.com.cn/news/2026/09/02/625299.html
  • 央视新闻(辽宁药监转载)— 视频丨国家药监局:药品追溯须覆盖全品种全链条: https://www.toutiao.com/article/7681111672232100387

Related reading

  • see also: China’s drug import licensing and GSP obligations for foreign MAHs (drug-import-licensing-gsp)
  • see also: medical-device UDI roll-out and the parallel “drug-device same-traceability” agenda (medical-device-udi)

药品追溯进入”全品种全链条”强监管:国家药监局2026年第85号公告解读

概述

2026年9月1日,国家药监局发布《关于进一步加强药品信息化追溯管理工作的公告》(2026年第85号,落款2026年8月31日)。公告依据《药品管理法》及其实施条例制定,把多年试点形成的基础设施升级为强制性、可执行的全链条制度:每个产品赋码、每个码必扫、每个环节可追责。药监局官员将药品追溯码形容为每一盒药的”电子身份证”,扫码即可记录和获取药品获批及生产流通环节的详细信息。

总原则:应赋尽赋、见码必扫

公告确立的总要求是”全品种赋码、应赋尽赋;全链条扫码、见码必扫”。覆盖面近乎全面:除原料药、医用氧、医疗机构制剂等少数品类外,全部在产制剂品种纳入追溯范围;中药饮片追溯要求另行制定。这意味着在华流通的进口制剂同样完全落入该制度,其持有人与境内责任人承担第一层义务。

各环节义务

持有人、境外持有人境内责任人。 须:通过国家药监局政务服务门户登录国家药品追溯协同服务平台,及时、准确、完整备案药品标识码,完成标识码、商品条码、本位码、医保编码等多码关联;按照”一物一码、物码同追”原则,在上市销售前完成追溯码赋码激活、各级销售包装单元追溯码关联并及时准确上传追溯信息;成品入库时在追溯系统保存入库信息,销售出库时向下游企业或使用单位提供追溯信息;及时处理下游反馈的追溯码异常信息,保障信息真实可信。

生产企业。 与持有人共同落实赋码激活与包装层级关联,及时准确上传信息。

批发企业。 入库验收时必须通过追溯系统向上游索取追溯信息、进行追溯码核对,将扫码核对作为入库验收的必须内容并反馈收货信息;出库复核时向下游企业或医疗机构提供追溯信息。

零售药店与医疗机构。 入库验收时与上游核对追溯码并反馈收货信息;销售时保存销售记录明细并及时上传销售信息;销售小票应显示追溯码或提供便捷查询渠道。追溯系统出现异常预警的,应立即停止入库和销售,核实处理并由质量负责人审核签字后实施,按GSP要求保存记录。入库验收发现追溯信息显示该药品已在其他零售或使用单位售出的,应当拒收。

追溯系统运营单位。 坚持公益性导向,保障数据安全;为持有人、境内责任人提供召回支持;为批发、零售、使用单位提供入库环节异常信号实时预警;对追溯信息中可能含有的个人隐私、商业秘密依法保密,不得泄露或非法提供;向国家平台备案确保追溯码唯一性。

监管与执法

公告要求各省级药监部门把追溯落实情况纳入对企业和单位的日常检查,督促做好全品种赋码激活与全链条扫码上传,做到”应赋尽赋、应扫尽扫”。对不落实法规规定、不符合追溯工作要求的,依照《药品管理法》《药品经营和使用质量监督管理办法》《药品经营质量管理规范》等严肃处理。公告强调”三医协同”(药监、医保、卫健),依托大数据智慧监管,提升风险发现与处置能力。数据安全要求明确:系统运营单位须依《数据安全法》建立数据安全管理制度。

对外资药企的意义

  • 追溯合规进入执法阶段,不再是”项目”。 进口制剂的外国持有人必须确保其境内责任人在国家平台完整运行赋码与上传闭环。境内责任人是持有人监管职能的延伸;责任人履职不力将直接拖累持有人整体在华合规态势。
  • 多码关联影响包装与IT工作。 标识码、商品条码、本位码、医保编码的关联意味着包装数据与ERP系统须在首次进口前与中国监管标识体系对齐。已带GS1条码的进口产品仍需完成中文标识码关联。
  • 合规玩家的渠道秩序改善。 “已在别处售出即拒收”与”异常预警即停售”直击回流药与串换编码乱象——这些乱象侵蚀合法定价体系。灰色渠道收窄,合规进口商受益。
  • 分销网络需具备GSP级文档能力。 分销商出入库扫码与质量负责人对异常预警的签字成为审计证据;外企应核实中国分销商系统确实能生成此类记录。
  • 与医保结算联动。 追溯与依码结算政策协同,扫码核验日益与报销、基金稽查挂钩;追溯数据不健全的产品在医院与医保渠道的报销可能受阻。

实务建议

  • 确认每个进口上市许可持有人的境内责任人在国家追溯协同平台登记有效,且每个在售SKU多码关联正确。
  • 审计包装与标签项目,确保追溯码、条码与层级关联在首次进入中国市场前完备。
  • 修订经销商合同,要求GSP合规的出入库扫码、异常预警处理与质量负责人签字记录。
  • 将内部ERP/质量系统与国家平台数据上传要求对齐,包括及时处理下游异常码反馈。
  • 跟踪省级执法动态与待出台的中药饮片追溯规则,并关注集采挂网与医院渠道中追溯与医保结算的衔接。

来源

  • 国家药监局 — 国家药监局关于进一步加强药品信息化追溯管理工作的公告(2026年第85号): https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260901134430105.html
  • 医药网 — 药品追溯新规出台 压实全产业链主体监管责任: https://news.pharmnet.com.cn/news/2026/09/02/625299.html
  • 央视新闻(辽宁药监转载)— 视频丨国家药监局:药品追溯须覆盖全品种全链条: https://www.toutiao.com/article/7681111672232100387

相关阅读

  • 见:外国持证人的药品进口许可与GSP义务(drug-import-licensing-gsp)
  • 见:医疗器械UDI分批强制与”药械同追”议程(medical-device-udi)

China’s renewable consumption mandates take effect: Order No. 42 of 2026 explained

  • Four central bodies — NDRC, MIIT, MOHURD and MOT — issued Order No. 42 of 2026 on 5 June 2026, publishing the Measures for Renewable Energy Minimum Consumption Share Targets and the Renewable Energy Power Consumption Responsibility Weight System, effective 1 August 2026.
    国家发展改革委、工业和信息化部、住房城乡建设部、交通运输部于2026年6月5日以2026年第42号令公布《可再生能源消费最低比重目标和可再生能源电力消纳责任权重制度实施办法》,自2026年8月1日起施行。
  • The Measures build two overlapping layers of obligation: minimum consumption-share targets for energy users in key energy-consuming industries, and renewable power consumption responsibility weights for each provincial-level region.
    《办法》构建两层叠加的约束体系:对重点用能行业能源用户设定可再生能源消费最低比重目标,对各省级行政区域设定可再生能源电力消纳责任权重。
  • For the first time, non-electric consumption is brought into the minimum-share assessment — including renewable heating and cooling, green hydrogen/ammonia/methanol and biofuel — extending the regime beyond the previous single focus on green power purchases.
    非电消费首次被纳入最低比重目标考核——涵盖可再生能源供热(制冷)、可再生能源制氢氨醇等综合利用、生物燃料——突破了此前单一考核绿电消费的格局。
  • The weights are optimised through region- and tier-based differentiation, strengthened medium- and long-term guidance, and firmer mandatory requirements, while the obsolete “excess consumption” and “incentive indicator” concepts are deleted.
    权重制度从实行分区分档、加强中长期引领、强化刚性要求三方面优化,同时删除”超额消纳量””激励性指标”等不再适用的内容。
  • Key industries already facing green-power share requirements include electrolytic aluminium, steel, cement, polysilicon and new data centres at national hub nodes; monitoring and assessment will expand across industry, construction and transport.
    已对电解铝、钢铁、水泥、多晶硅和国家枢纽节点新建数据中心等提出绿色电力消费比例要求;监测考核将向工业、建筑、交通等消费侧重点领域扩展。
  • For foreign-invested manufacturers and data-centre operators in China, the practical effect is a shift of compliance pressure to the electricity buyer: renewable-power purchase, on-site green generation, storage-supported consumption and green certificates all become levers for meeting hard, measurable targets.
    对在华外资制造商与数据中心运营者而言,实际影响是合规压力下移至用电方:购买绿电、就地绿电生产、以储能支撑消纳以及绿证,都成为满足硬性可度量目标的工具。

China’s renewable consumption mandates take effect: Order No. 42 of 2026 explained | 可再生能源消费硬考核落地:2026年第42号令实施办法解读

Overview

On 5 June 2026 the National Development and Reform Commission (NDRC), the Ministry of Industry and Information Technology (MIIT), the Ministry of Housing and Urban-Rural Development (MOHURD) and the Ministry of Transport (MOT) jointly issued Order No. 42 of 2026, publishing the Measures for Renewable Energy Minimum Consumption Share Targets and the Renewable Energy Power Consumption Responsibility Weight System (可再生能源消费最低比重目标和可再生能源电力消纳责任权重制度实施办法). The Measures took effect on 1 August 2026.

The legal base is the Energy Law and the Renewable Energy Law. The policy intent is to guide society toward preferring and actively consuming renewable energy, promote its high-quality development, and support the carbon-peak and carbon-neutrality goals. The mechanism turns those macro objectives into quantified, assessable obligations at two levels: energy users in key industries, and provincial-level regions.

Two layers of obligation

Layer 1 — Minimum consumption share targets for energy users

The Measures establish a minimum-share system for energy users in key energy-consuming industries. The minimum renewable share is expressed as the share of renewables in an energy user’s total energy consumption, split into two categories:

  • Electricity minimum-share targets, covering all renewable power-generation types; and
  • Non-electric minimum-share targets, covering renewable heating and cooling, comprehensive utilisation such as green hydrogen/ammonia/methanol produced from renewables, and biofuels.

The central energy authority, together with the relevant departments, determines the key industries, issues targets year by year, and monitors, evaluates and assesses compliance. Industries already facing green-power share requirements include electrolytic aluminium, steel, cement, polysilicon and new data centres at national computing-hub nodes. Going forward, assessment is expected to focus on industry, construction and transport — the main consumption-side sectors. The state encourages enterprises in key industries to go above the minimum, and encourages localities with the right conditions to set minimum shares for government bodies, public institutions and state-owned enterprises.

Layer 2 — Consumption responsibility weights for provincial regions

The renewable power consumption responsibility weight system sets, for every provincial-level region, an explicit target for the share of electricity the region consumes that must come from renewables. The Measures optimise the weight system in three ways:

  • Region- and tier-based differentiation (分区分档), so weights reflect each region’s resource endowment and consumption reality;
  • stronger medium- and long-term guidance, anchoring multi-year expectations for investors; and
  • firmer mandatory requirements, turning consumption responsibility into a hard constraint that protects priority consumption of green power.

Outdated concepts such as “excess consumption” (超额消纳量) and “incentive indicators” (激励性指标) are deleted.

Why the non-electric expansion matters

Until now, China’s assessment of green consumption focused on green power. The 2026 Measures, for the first time, fold non-electric renewable consumption into the minimum-share assessment. The reasoning, per the National Energy Administration, is that renewable non-electric utilisation is essential to relieving grid-consumption pressure in resource-rich regions with limited local demand and to expanding end-use decarbonisation. For companies, this means:

  • renewable heating and cooling can count toward targets;
  • green hydrogen, ammonia and methanol produced from renewable power qualify as non-electric renewable consumption; and
  • biofuel use counts as well.

For foreign investors, the significance is that the decarbonisation compliance toolbox is now broader: a manufacturer that cannot buy enough green power may still move toward its target through on-site renewable heat, green-hydrogen projects or biofuel substitution.

What changed for the market

NDRC’s Energy Research Institute frames the Measures as building a “consumption-end + absorption-end” guarantee system for the first time, closing the loop through target setting, responsibility allocation, implementation paths and supervision. Key market consequences:

  • Compliance pressure moves to the buyer. Unlike earlier eras that pushed storage or generation obligations onto new renewable plants, the new regime pushes consumption targets onto electricity users. Industrial users now need green-power purchase agreements (PPAs), on-site generation, storage-supported consumption, or green certificates to demonstrate compliance.
  • Storage demand is stimulated indirectly. Industrial users that must consume a minimum renewable share may install storage to time-shift green power, and grid-side long-duration storage is needed to help provinces meet absorption weights.
  • New-economy sectors are pulled in. Computing infrastructure, 5G base stations and charging infrastructure are expected to be drawn into assessment, directing clean electricity toward covering incremental electricity demand.
  • “Green builds green.” New-energy manufacturing itself — polysilicon, lithium-battery manufacturing — faces green-consumption requirements, building a low-carbon supply chain for clean-energy equipment.

What this means for foreign-invested enterprises

For foreign manufacturers, data-centre operators and industrial investors in China, the Measures are a compliance milestone:

  • Data centres and heavy industry are in scope now or soon. Polysilicon, steel, cement, electrolytic aluminium and new national-hub data centres already face green-power share requirements; industry, construction and transport are the declared next frontier. Foreign plants in these sectors should treat renewable procurement as a compliance item, not an ESG option.
  • The toolbox is wider than PPAs. On-site renewable heat, green hydrogen/ammonia/methanol, biofuels and storage-supported green-power consumption can all contribute. Model each option against your load profile.
  • Provincial weight differences matter for site selection. Because weights are set region by region, the effective cost of meeting a target differs across provinces. Renewable resource endowment, grid conditions and local green-power prices should feed into any new-plant location decision.
  • Green certificates and PPAs become verifiable instruments. Expect more rigorous monitoring and assessment; keep the certificates, contracts and consumption data that demonstrate compliance in a form regulators can audit.

Practical steps

  • Determine whether your facility or project falls within a designated key energy-consuming industry and which year-by-year targets apply.
  • Map current electricity and heat consumption against the target; quantify the gap in renewable share terms.
  • Evaluate procurement routes: green-power PPAs, on-site solar or wind, storage-supported consumption, and green certificates, including cost and availability in your province.
  • For data-centre and manufacturing expansions, model renewable-consumption cost into the site-selection process rather than treating it as an afterthought.
  • Build a compliance evidence file — contracts, certificates and monthly consumption data — ahead of the monitoring and assessment cycles.

Sources

  • 中国政府网(国务院公报) — 可再生能源消费最低比重目标和可再生能源电力消纳责任权重制度实施办法(国家发展改革委等四部门令2026年第42号全文): https://www.gov.cn/gongbao/2026/issue_12926/202608/content_7078436.html
  • 中国发展门户网 — 最低比重目标制度首次建立——可再生能源电力消纳迎硬考核: https://cn.chinagate.cn/environment/2026-08/26/content_118664400.shtml
  • 中国发展门户网 — 可再生能源消费最低比重目标与消纳责任权重制度相关报道: https://cn.chinagate.cn/environment/2026-08/19/content_118654154.shtml

Related reading

  • see also: The new power system “15th Five-Year” plan — targets and entry points (330-new-power-system-15th-fyp)
  • see also: China’s carbon market enters its next phase (311-carbon-market-expansion)

可再生能源消费硬考核落地:2026年第42号令实施办法解读

概述

2026年6月5日,国家发展改革委、工业和信息化部、住房城乡建设部、交通运输部联合发布2026年第42号令,公布《可再生能源消费最低比重目标和可再生能源电力消纳责任权重制度实施办法》,自2026年8月1日起施行。

其法律依据是《能源法》与《可再生能源法》。政策意图是引导全社会优先使用和主动消费可再生能源,推动可再生能源高质量发展,助力实现碳达峰碳中和。该机制将宏观目标转化为两个层面可量化、可考核的义务:重点用能行业的能源用户,以及省级行政区域。

两层义务

第一层——能源用户消费最低比重目标

《办法》建立重点用能行业能源用户的可再生能源消费最低比重制度。最低比重指国家规定能源用户消费的可再生能源在其总能源消费中应达到的最低比例,分为两类:

  • 电力消费最低比重目标,涵盖全部可再生能源发电种类;
  • 非电消费最低比重目标,涵盖可再生能源供热(制冷)、可再生能源制氢氨醇等综合利用、生物燃料等可再生能源非电利用种类。

国务院能源主管部门会同有关部门确定重点用能行业,按年下达目标,并进行监测、评价和考核。已对电解铝、钢铁、水泥、多晶硅和国家枢纽节点新建数据中心等提出绿色电力消费比例要求。未来考核重点将聚焦工业、建筑和交通等消费侧重点领域。国家支持重点企业在此基础上进一步提升消费比例,鼓励具备条件的地区对政府部门、事业单位、国有企业提出最低比重目标。

第二层——省级消纳责任权重

可再生能源电力消纳责任权重制度,是对每个省级行政区域设定明确的可再生能源电量消纳目标,以刚性约束保障绿色电力优先消纳。《办法》从三方面优化权重制度:

  • 分区分档,使权重反映各地区资源禀赋与消纳实际;
  • 加强中长期引领,为投资者锚定多年预期;
  • 强化刚性要求,把消纳责任变为保护绿电优先消纳的硬约束。

同时删除”超额消纳量””激励性指标”等不再适用的内容。

非电扩围为何重要

此前中国对绿色消费的考核聚焦绿电。2026年《办法》首次将非电可再生能源消费纳入最低比重目标考核。国家能源局给出的理由是:在资源富集地区本地消纳能力有限、大规模远距离外送制约增多的背景下,拓展可再生能源非电利用途径,既是缓解电网消纳压力、破解电力消纳瓶颈的需要,也是深入推进可再生能源安全可靠替代的内在要求。对企业而言,这意味着:

  • 可再生能源供热(制冷)可以计入目标;
  • 由可再生能源电力制取的绿氢、绿氨、绿醇属合格的非电可再生能源消费;
  • 生物燃料使用同样计入。

对外国投资者而言,关键是脱碳合规工具箱变宽了:买不到足够绿电的制造商,仍可通过就地可再生热能、绿氢项目或生物燃料替代向目标靠拢。

市场影响

国家发展改革委能源研究所将《办法》概括为首次从”消费端+消纳端”双维度构建可再生能源保障体系,通过目标设定、责任分工、实现路径与考核监管形成全链条闭环。主要市场影响:

  • 合规压力下移至用电方。 与早期把储能或发电义务压给新建新能源电站不同,新机制把消费目标压到用电户身上。工业企业如今需要绿电交易协议(PPA)、就地发电、储能支撑消纳或绿证来证明合规。
  • 间接带动储能需求。 须满足最低消费比重的工业企业可能加装储能以移峰填谷消纳绿电;电网侧长时储能则是省份完成消纳权重的需要。
  • 新经济领域被纳入。 算力设施、5G基站、充电基础设施预计将进入考核,推动清洁电力覆盖全社会用电增量。
  • “以绿造绿”。 多晶硅、锂电池制造等新能源制造业本身也要满足绿色消费要求,为清洁能源装备构建上下游协同减碳的绿色产业链供应链。

对外资企业的意义

对在华外资制造商、数据中心运营者与工业投资者而言,《办法》是一座合规里程碑:

  • 数据中心与重工业现在或即将入考。 多晶硅、钢铁、水泥、电解铝和国家枢纽节点新建数据中心已面临绿电比例要求;工业、建筑与交通被明确列为下一站。上述行业的外资工厂应把可再生电力采购当作合规事项,而非ESG选项。
  • 工具箱不止PPA。 就地可再生热能、绿氢氨醇、生物燃料与储能支撑的绿电消费均可作贡献。请结合自身负荷画像逐项测算。
  • 省级权重差异影响选址。 权重分省设定,各地达标成本不同。可再生资源禀赋、电网条件与当地绿电价格都应纳入新厂选址决策。
  • 绿证与PPA成为可核验凭证。 监测考核将更严格;请以监管可审计的形式留存合同、绿证与消费数据。

实务建议

  • 判断本企业或项目是否属于重点用能行业范围,以及适用的分年度目标。
  • 对照目标梳理当前电力与热力消费,量化可再生占比缺口。
  • 评估采购路径:绿电PPA、就地光伏或风电、储能支撑消费与绿证,并比较所在省份的成本与可获得性。
  • 数据中心与制造扩建中,把可再生消费成本纳入选址模型,而非事后补救。
  • 在监测考核周期到来前建立合规证据档案——合同、绿证与逐月消费数据。

来源

  • 中国政府网(国务院公报) — 可再生能源消费最低比重目标和可再生能源电力消纳责任权重制度实施办法(国家发展改革委等四部门令2026年第42号全文): https://www.gov.cn/gongbao/2026/issue_12926/202608/content_7078436.html
  • 中国发展门户网 — 最低比重目标制度首次建立——可再生能源电力消纳迎硬考核: https://cn.chinagate.cn/environment/2026-08/26/content_118664400.shtml
  • 中国发展门户网 — 可再生能源消费最低比重目标与消纳责任权重制度相关报道: https://cn.chinagate.cn/environment/2026-08/19/content_118654154.shtml

相关阅读

  • 见:新型电力系统”十五五”规划——目标与切入点(330-new-power-system-15th-fyp)
  • 见:全国碳市场进入新阶段(311-carbon-market-expansion)

Hainan after closure: the 23rd batch of institutional-innovation cases and what the numbers show

  • Hainan has now cultivated 23 batches totalling 188 institutional-integration innovation cases, of which 87 have been recognised at the national level and 43 promoted nationwide, according to the province’s 29 August 2026 press conference in Changchun.
    据海南2026年8月29日在长春举行的专场新闻发布会介绍,海南自贸港已累计培育形成23批188项制度集成创新案例,其中87项获国家层面认可、43项向全国推广。
  • The 23rd batch — released as the first cases focused on the island-wide closure operation — covers the “second-line port” operating system, the zero-tariff tax-collection model, split-line customs clearance, anti-smuggling governance, joint inspection and quarantine risk control, and the Yangpu ship-registry service chain.
    第23批案例是首批聚焦全岛封关运作的制度集成创新,涵盖”二线口岸”运行管理体系、”零关税”税收征管模式、分线管理通关、”二线”反走私与沿海安全治理、检验检疫风险联合防控以及”中国洋浦港”船籍港管理服务全链条。
  • Behind the “second-line port” system, outbound declarations from Hainan were cut from 105 items to 42, and average lorry security screening at the Xinhaigang and Nangang freight yards fell to about 70 seconds.
    在”二线口岸”运行管理体系下,”二线”出岛申报项目由105项降至42项,海口新海港和南港货运集中查验场货车安检平均时长已优化至约70秒。
  • Zero-tariff uptake is accelerating: by 30 June 2026, 93 beneficiary entities had declared RMB 3.437 billion of zero-tariff imports, up 53.6% year on year, and the share of items eligible for zero-tariff treatment was raised from 21% to 74%.
    “零关税”政策红利加快释放:截至2026年6月30日,93家享惠主体申报进口”零关税”货物34.37亿元,同比增长53.6%;适用零关税的税目比例从21%大幅提高到74%。
  • In the shipping pillar, the “China Yangpu Port” registry passed 100 internationally trading ships on 18 August 2026 — total capacity above 8.9 million deadweight tonnes — with 33 high-frequency administrative items now processed across departments in one integrated flow.
    航运领域,”中国洋浦港”船籍港登记在册国际航行船舶于2026年8月18日突破100艘、总运力超890万载重吨;33项高频政务事项实现跨部门集成办理。
  • For foreign investors the takeaway is operational: post-closure Hainan is moving from policy design to measurable clearance and tax mechanics, and the cases themselves signal where the province will keep simplifying trade, investment and ship-related procedures.
    对外国投资者而言,要点在于实操层面:封关后的海南正从政策设计走向可度量的通关与税收机制,而案例本身也预示着海南将继续在贸易、投资与航运手续上做简化。

Hainan after closure: the 23rd batch of institutional-innovation cases and what the numbers show | 封关后的海南:第23批制度集成创新案例与数据背后的信号

Overview

At a 29 August 2026 press conference in Changchun held under the banner “Building the Hainan Free Trade Port to a High Standard” (高标准建设海南自由贸易港), Hainan’s provincial leadership took stock of the institutional innovation that has accompanied the free trade port’s island-wide closure operation. The headline figures: Hainan has now cultivated 23 batches totalling 188 institutional-integration innovation cases, of which 87 have been recognised at the national level and 43 promoted nationwide.

The 23rd batch matters for a specific reason: it is the first batch built around the closure operation itself. Released in late July 2026 as six cases, it shows how Hainan is making the “first line opens wide, second line is efficiently controlled” design work in practice — which is exactly the machinery foreign companies now deal with when moving goods, aircraft, ships or investment through the island.

The six cases of the 23rd batch

1. The “second-line port” operating system

The closure created China’s first “second-line ports” — the ten customs-supervised cargo inspection points through which zero-tariff goods and their processed products, duty-deferred processing goods and other not-yet-cleared cargo must pass to enter the mainland market. The innovation case gives the concept a complete definition and a standardised operating mechanism, filling a gap in national practice.

The measurable results are striking. Outbound declaration items were cut from 105 to 42, lifting average declaration efficiency by more than 70%. At the freight inspection yards of Haikou’s Xinhaigang (new port) and Nangang, the average security-screening time for lorries has been optimised to about 70 seconds. Supervision follows a “1+N” model in which customs conducts routine control while maritime, border-inspection and port operators cooperate, and non-core port functions such as animal and plant quarantine are pushed forward or moved online.

2. Innovation in zero-tariff goods tax collection

Hainan built an intelligent supervision system described as “one person one code, one enterprise one account, one item one chain, one call one response” (一人一码、一企一账、一物一链、一呼一应). Uptake data show the policy gaining momentum: from closure to 30 June 2026, 93 beneficiary entities declared RMB 3.437 billion of zero-tariff imports, up 53.6% year on year. The share of tariff items eligible for zero-tariff treatment was substantially widened from 21% to 74%, and related tax relief has grown accordingly.

3. Split-line customs clearance (“first line in, second line out”)

Under the new clearance model, Hainan is testing “direct release” (径予放行) ultra-simple declaration, “batch departure with consolidated declaration” (分批出岛、集中申报), and simplified second-line declaration — delivering “minimal formalities at the first line, convenient exit at the second line”. From closure to 30 June 2026, five enterprises used the direct-release model to import 70,000 tonnes of goods worth RMB 270 million, and 13 enterprises shipped more than 1,700 batches of goods to the mainland under the batch-departure model.

4. Anti-smuggling and coastal security governance at non-designated points

Hainan says it is the first in the country to build a law-based, all-domain anti-smuggling governance chain covering land, sea and air. Since 2025, authorities have proactively detected and transferred 2,863 leads involving violations, and dealt with 1,494 “three-no” vessels (ships without name, registration or port-of-call papers).

5. Joint inspection and quarantine risk control — “one trigger, multi-point response”

A multi-department coordination mechanism means a risk signal detected by one agency immediately triggers linked action across the island. Since the mechanism was established in March 2025, customs and local authorities have shared 2,377 risk messages and jointly handled 33 risk incidents.

6. “China Yangpu Port” ship-registry service chain

The case consolidates 33 high-frequency administrative matters into cross-department, integrated processing. The registry’s numbers continue to lead all national free trade zones and ports: on 18 August 2026 the “China Yangpu Port” registry passed 100 internationally trading ships, with total capacity exceeding 8.9 million deadweight tonnes. Ship safety remains strong, with a zero-detention record and one of the country’s highest shares of safety-integrity ships.

The wider picture: 188 cases and what they mean for business

The Changchun conference used several representative cases to show how the innovation stock translates into operating convenience:

  • Trade and investment liberalisation. Hainan issued the country’s first cross-border services trade negative list and the shortest foreign-investment access negative list on the mainland, set up the first national “single window” for international investment, and fully implemented ultra-simple approval, coordinated with the national “efficient handling of one thing” reform.
  • “Repair the world’s aircraft in Hainan.” Aviation maintenance has become a signature industry: by the end of 2025, 2,400 aircraft movements had been repaired in Hainan, import-export value passed RMB 100 billion, and the service network covers nearly 50 large airlines globally, saving operators an estimated 10–15% in total cost.
  • Emerging industries. The commercial spaceport completed 21 commercial launches with a world-first sea-based recovery breakthrough; the “Nanfan Silicon Valley” has created a special IP zone for seed industry, attracting leading seed companies and innovative SMEs.
  • Factor services. Hainan’s “land supermarket” — upgraded into a “natural resources supermarket” covering land, sea and mineral elements — lets enterprises read, select and buy land on a cloud platform, backed by an integrated smart-governance map.

The underlying message is that closure did not pause reform; it shifted the frontier from policy design to operational mechanics. Provincial officials say the next stage will focus on aligning with high-standard international economic and trade rules, advancing the compatibility of rules, regulations, management and standards, and further lowering the cost of cross-border investment and operations.

What foreign companies should watch

  • Declaration simplification is real and measurable. The drop from 105 to 42 declaration items and the 70-second lorry screening are the kind of operational figures that should be fed directly into logistics and customs-clearance planning for any goods moving between Hainan and the mainland.
  • Zero-tariff eligibility has widened materially. With the eligible item share up from 21% to 74%, companies that earlier concluded their goods were outside the zero-tariff list should re-test eligibility under the expanded scope.
  • The ship-registry play is maturing. With over 100 internationally trading ships and integrated cross-department processing, “China Yangpu Port” remains the entry point for shipping companies considering Hainan registration, reinforced by zero-tariff vessel import and VAT refunds on new builds.
  • Expect more rule-alignment measures. The stated direction — rule, regulation, management and standard compatibility with international high-standard trade rules — points to continued simplification of cross-border services and investment procedures.

Practical steps

  • Re-screen product eligibility against the widened zero-tariff item scope and the second-line declaration regime before structuring mainland-bound shipments from Hainan.
  • Benchmark logistics routes against the new clearance times at Xinhaigang and Nangang; update customs brokers on the simplified declaration options (direct release, batch departure with consolidated declaration).
  • For shipping operations, evaluate Yangpu registration against the current integrated 33-item service chain, zero-tariff vessel import and the registry’s safety record.
  • Monitor the next batches of innovation cases: each batch tends to convert a policy idea into concrete, time-and-cost-relevant procedures for foreign-invested business.

Sources

  • 海南省人民政府网 — “高标准建设海南自由贸易港”(长春市)专场新闻发布会实录: https://www.hainan.gov.cn/hainan/szdf/202608/26b67c827cdd48e49007f2fd2f9a7228.shtml
  • 海南省交通运输厅 — 百舸争流启新程!”中国洋浦港”籍国际船舶突破100艘: https://jt.hainan.gov.cn/ywdt_384/xxlb/202608/t20260818_4130419.html
  • 中国新闻网 — 海南封关看变化:制度集成创新打造新时代改革开放新高地: https://www.chinanews.com.cn/cj/2026/08-30/10686700.shtml

Related reading

  • see also: Hainan’s “15th Five-Year Plan” for the international tourism consumption centre (342-hainan-tourism-15th-fyp)
  • see also: Hainan moves to codify “zero-tariff” resident duty-free shops (306-hainan-zero-tariff-duty-free)

封关后的海南:第23批制度集成创新案例与数据背后的信号

概述

2026年8月29日,在长春举行的”高标准建设海南自由贸易港”专场新闻发布会上,海南省层面系统盘点了伴随全岛封关运作推进的制度集成创新成果。核心数字:海南已累计培育形成23批188项制度集成创新案例,其中87项获国家层面认可、43项向全国推广。

第23批案例之所以特殊,在于它是首批围绕封关运作本身打造的案例。2026年8月13日,海南自由贸易港举行制度集成创新案例(第23批)新闻发布会,聚焦封关运作领域发布6项案例,展示海南如何把”一线放开、二线管住”的设计落到实操——而这正是外国企业如今在海南流转货物、飞机、船舶或开展投资时所面对的具体机制。

第23批的六项案例

一、”二线口岸”运行管理体系

封关创设了中国首批”二线口岸”——10个经海关监管的货物查验点,”零关税”货物及其加工制成品、加工增值免关税保税货物及其他未办结海关手续的货物须经此处进入内地市场。该项创新给出”二线口岸”的完整释义,并建立规范化运行管理机制,填补了国内制度空白。

成效数据直观:出岛申报项目由105项降至42项,企业平均申报效率提升70%以上;海口新海港和南港货运集中查验场货车安检平均时长已优化至约70秒。监管实行”1+N”模式——海关常规监管为主,海事、边检、港口运营单位协同共管,动植物检疫等非口岸核心功能前推或移至线上办理。

二、”零关税”货物税收征管模式创新

海南构建”一人一码、一企一账、一物一链、一呼一应”智能监管体系。数据显示政策红利加快释放:封关运作至2026年6月30日,93家享惠主体申报进口”零关税”货物34.37亿元,同比增长53.6%;适用零关税的税目比例由21%大幅提高到74%,相应减免税款同步增长。

三、全岛封关分线管理通关新模式

围绕”一线极简进、二线便利出”,海南探索”径予放行”极简申报、”分批出岛、集中申报”和”二线”简化申报等通关便利化举措。封关至2026年6月30日,5家企业以”径予放行”模式进口货物7万吨、货值2.7亿元;13家企业以”分出集报”模式向内地出岛内销货物超1700批次。

四、非设关地反走私与沿海安全综合治理新模式

海南在全国率先构建贯通陆海空全域全链条的反走私法治化治理体系。2025年以来,主动查获移交各类违法违规线索2863条,查处”三无”船舶1494艘。

五、检验检疫风险联合防控”一点触发、多点联动”

建立多部门协同联动机制:一处发现风险信号,全岛即时联动处置。自2025年3月机制建立以来,海关与地方共享风险信息2377条,联合处置风险事件33起。

六、”中国洋浦港”船籍港管理服务全链条创新

该项案例整合33项高频政务事项,实现跨部门集成办理。船籍港数据继续领跑全国自贸区(港):2026年8月18日,”中国洋浦港”登记在册国际航行船舶突破100艘,总运力超过890万载重吨;船队保持零滞留纪录,安全诚信船舶占比居全国前列。

更大图景:188项案例与商业含义

长春发布会用多个代表性案例说明制度创新储备如何转化为经营便利:

  • 贸易投资自由化便利化。 海南出台全国首张跨境服务贸易负面清单和中国内地最短外商投资准入负面清单,建立全国首个国际投资”单一窗口”,全面推行极简审批制度,并与”高效办成一件事”改革深度协同。
  • “在海南自贸港修全球飞机”。 航空维修已成标志性产业:截至2025年底,2400架次飞机在海南完成维修,进出口值突破1000亿元,服务网络覆盖全球近50家大型航空公司,可为企业节省10%到15%的综合成本。
  • 特色优势产业。 海南商业航天发射场完成21发商业发射任务,实现全球首创火箭海上回收突破;”南繁硅谷”创建种业知识产权特区,吸引大批种业龙头与创新型中小企业。
  • 要素保障服务。 “土地超市”升级为覆盖用地、用海、用矿的”自然资源超市”,企业可在云平台读地、选地、买地,配套”国土空间智慧治理一张网”。

核心信号是:封关并未让改革停步,而是把前沿从政策设计推向运行机制。官方表示,下一阶段将对接国际高标准经贸规则,推动规则、规制、管理、标准等相通相容,进一步降低企业跨境投资与经营成本。

外国企业应关注什么

  • 申报简化是真实可度量的。 申报项目从105项降至42项、货车安检缩短至70秒——这类运营数据应直接用于任何经海南进出内地的物流与通关规划。
  • 零关税适用范围显著扩大。 适用税目比例从21%升至74%,此前判定货物不在零关税清单内的企业,应在扩围后重新核验资格。
  • 船籍港故事走向成熟。 登记国际航行船舶破百艘并实现跨部门集成办理,”中国洋浦港”依然是考虑海南注册的航运企业的入口,叠加船舶”零关税”进口与新造船增值税退税政策。
  • 可期待更多规则衔接措施。 官方明确的方向——与国际高标准经贸规则的规则、规制、管理、标准相容——预示着跨境服务与投资手续将继续简化。

实务建议

  • 在规划从海南发往内地的货物前,对照扩围后的零关税税目范围与”二线”申报制度重新筛查产品资格。
  • 依据新海港、南港新的通关时长基准调整物流路线;向报关代理确认简化申报选项(径予放行、分批出岛集中申报)。
  • 航运企业可对照当前33项集成服务链、”零关税”船舶进口与船籍港安全记录,评估在洋浦注册的可行性。
  • 持续跟踪后续批次的创新案例:每一批往往会把一个政策构想转化为对外资企业有时效和成本意义的具体程序。

来源

  • 海南省人民政府网 — “高标准建设海南自由贸易港”(长春市)专场新闻发布会实录: https://www.hainan.gov.cn/hainan/szdf/202608/26b67c827cdd48e49007f2fd2f9a7228.shtml
  • 海南省交通运输厅 — 百舸争流启新程!”中国洋浦港”籍国际船舶突破100艘: https://jt.hainan.gov.cn/ywdt_384/xxlb/202608/t20260818_4130419.html
  • 中国新闻网 — 海南封关看变化:制度集成创新打造新时代改革开放新高地: https://www.chinanews.com.cn/cj/2026/08-30/10686700.shtml

相关阅读

  • 见:海南”十五五”国际旅游消费中心规划(342-hainan-tourism-15th-fyp)
  • 见:海南推动”零关税”岛内居民免税店成文化(306-hainan-zero-tariff-duty-free)

Nansha’s four-channel pitch to Macao: equipment, talent, capital and daily life

  • At a 25 August 2026 joint media briefing in Guangzhou Nansha, officials set out a four-channel framework for deepening Nansha–Macao cooperation: equipment mobility (设备通), talent mobility (人畅通), capital mobility (资金通) and daily-life integration (生活通).
    2026年8月25日,中央港澳办”对接’十五五’发挥新优势”主题联合采访走进广州南沙,南沙开发区(自贸区南沙片区)管委会方面提出深化粤澳合作的”四通”框架:设备通、人畅通、资金通、生活通。
  • Macao’s third five-year plan explicitly proposes exploring the joint construction of a special cooperation platform with Nansha and a Guangdong–Macao vehicle-export platform, giving the two sides a concrete work agenda for the “15th Five-Year Plan” period.
    澳门第三个五年规划明确写入”积极探索与南沙等地共建特色合作平台、研究粤澳共同建设汽车出海平台”,为”十五五”时期两地协作给出具体工作议程。
  • On equipment, Nansha is the first in the country to pilot cross-border mobility supervision for duty-exempt research equipment, using a “one application, valid across the project” filing model so Macao research teams can move kit in and out flexibly over a research cycle.
    设备方面,南沙在全国率先探索减免税科研设备跨境流动监管创新,推出”一次申请、项目内通用”备案模式,让澳门科研团队可在整个研究周期内灵活跨境调配设备。
  • On talent, the recognised list of overseas professional qualifications now covers 248 items with a “practice first, file later” model; Macao residents working in Nansha who already contribute to Macao’s social-security fund are exempt from parts of mainland employee pension and unemployment insurance, and personal-income-tax above the Macao level is waived.
    人才方面,境外职业资格认可清单扩至248项并推行”先执业、后备案”;已在南沙就业且已参加澳门社保基金的澳门居民,可免缴部分内地职工养老保险与失业保险,其个人所得税税负超过澳门税负的部分免征。
  • On capital and life, the cross-border trade and investment high-level opening pilot has seen cumulative transactions above USD 62 billion, and a Guangdong–Macao social-security “one-window” counter handles 66 Guangdong and 31 Macao social-security services, including cross-border collection of Macao benefits.
    资金与生活方面,跨境贸易投资高水平开放试点累计交易额超620亿美元;”粤澳社保一窗通”专窗可同时办理66项广东社保和31项澳门社保服务,含澳门福利跨境领取。
  • For Hong Kong, Macao and foreign companies looking at the Greater Bay Area, Nansha’s pitch is now concrete: an 803-square-kilometre zone in the geometric centre of the bay area that is packaging duty-free research-equipment mobility, cross-border professional practice, financial convenience and social-security portability into one investment location.
    对有意布局大湾区的港澳与外国企业而言,南沙的招商叙事如今很具体:803平方公里、地处大湾区地理几何中心,正在把免税科研设备流动、跨境执业、金融便利与社保衔接打包进同一投资目的地。

Nansha’s four-channel pitch to Macao: equipment, talent, capital and daily life | 南沙对澳”四通”框架:设备、人才、资金与生活

Overview

On 25 August 2026, a joint media tour organised by the Hong Kong and Macao Affairs Office of the CPC Central Committee — themed “Aligning with the 15th Five-Year Plan, Unleashing New Advantages” — visited Guangzhou’s Nansha district. In a briefing, Nansha Development Zone (Guangdong FTZ Nansha Area) management committee officials set out how the zone intends to deepen cooperation with Macao across four channels: equipment mobility, talent mobility, capital mobility and daily-life integration — in the shorthand of the briefing, “设备通、人畅通、资金通、生活通”.

The framework responds directly to Macao’s own third five-year plan, which proposes “actively exploring the joint construction of special cooperation platforms with Nansha and elsewhere, and studying the joint construction of a Guangdong–Macao vehicle-export platform”. That single sentence in Macao’s plan gives Nansha a concrete work agenda, and the zone is now turning it into serviceable policy.

Channel 1 — Equipment mobility (设备通)

Cross-border research is often blocked by equipment: Macao scientists collaborating with mainland institutions need to bring instruments and apparatus into Guangdong and, ideally, move them back and forth as projects evolve. Nansha’s answer is the first national pilot for cross-border mobility supervision of duty-exempt research equipment, built around a “one application, valid across the project” (一次申请、项目内通用) filing model. A research team files once for a project and may then move the equipment in and out flexibly during the whole research cycle, reporting usage on a quarterly basis. This removes the friction of re-approval for each movement and is designed to make Macao research teams more willing to run joint programmes with mainland partners in Nansha.

Channel 2 — Talent mobility (人畅通)

Two mechanisms carry this channel:

  • Professional qualifications. Nansha implements the “Greater Bay Area Pass” project to remove blockages in standard certification, cross-border practice, data flow and clearance. The recognised list of overseas professional qualifications has grown to 248 items, and a “practice first, file later” (先执业、后备案) model lets Macao professionals start practising in Nansha without waiting for a pre-approval cycle, filing afterwards.
  • Social insurance and tax. Macao residents working in Nansha who already contribute to Macao’s social-security fund are exempt from participating in mainland employee basic pension insurance and unemployment insurance. Macao residents working in Nansha are also exempt from personal income tax to the extent their tax burden exceeds what they would pay in Macao. For Macao professionals this materially improves net pay and removes the double-contribution problem.

Channel 3 — Capital mobility (资金通)

Nansha’s financial story rests on the cross-border trade and investment high-level opening pilot, whose cumulative transaction volume has exceeded USD 62 billion. The zone wants to build out sci-tech finance, industry-chain finance and supply-chain finance as its signature specialisations, accelerating convenient cross-border fund flows for Macao companies setting up in Nansha. On the trade side, Nansha Port has built a route network connecting Portuguese-speaking countries, and a Guangdong–Macao–Portuguese-speaking-countries quality food supply-chain centre has located in Nansha — a practical bridge for Macao’s role as the China-Portugal platform.

Channel 4 — Daily-life integration (生活通)

The final channel is about making Nansha a place Macao people can actually live in:

  • A Guangdong–Macao social-security “one-window” counter (粤澳社保一窗通专窗) handles 66 Guangdong social-security services and 31 Macao services in one place, including cross-border collection of Macao benefits such as the “two pensions, five subsidies” and central provident fund, with cross-border remittance fees waived.
  • Supporting schemes such as “Greater Bay Area Social Security Pass” and “Hong Kong/Macao Medicines and Medical Devices Connect” (港澳药械通) extend the convenience into healthcare — Macao residents in Nansha can see doctors using Hong Kong/Macao-registered medicines and devices, with related insurance arrangements.
  • Nansha reports over 3,100 Hong Kong and Macao enterprises already located in the zone and more than 11,000 Hong Kong and Macao residents.

The two sides framed the effort in deliberately human terms: “the alignment of institutions is for the closeness of hearts; the opening of channels is for the continuity of friendship.”

What this means for investors

For Hong Kong, Macao and foreign companies evaluating the Greater Bay Area, the four-channel framework is worth reading as an investment-location signal:

  • R&D-intensive firms get an equipment story. If your work involves bringing instruments into China for joint research, the “one application, project-wide” pilot is a genuine operational advantage compared with per-movement approval elsewhere.
  • Talent-heavy businesses should price the tax and social-insurance package. The Macao resident tax exemption and social-insurance treatment directly lower the cost of Macao hires, which matters for professional-services, healthcare and education ventures relying on Macao talent.
  • Vehicle-export and Portuguese-speaking-market players should watch the pipeline. The proposed Guangdong–Macao vehicle-export platform and the Portuguese-speaking supply-chain centre suggest Nansha is positioning itself as the bay area’s gateway for Macao-linked trade routes.
  • The social-security one-window reduces the “stickiness” problem. Cross-border benefit collection and fee-free remittances lower the personal cost of relocating staff, which improves retention for companies moving Macao employees to Nansha.

Practical steps

  • If your company runs joint research with Macao institutions, ask the Nansha authorities about the duty-exempt research-equipment filing model and the quarterly usage reporting requirement.
  • When hiring Macao professionals, confirm their Macao social-security-fund status up front and model the mainland social-insurance exemption and personal-income-tax difference into the compensation package.
  • Monitor the vehicle-export platform and Portuguese-speaking supply-chain initiatives for concrete application windows and subsidy schemes.
  • For staff relocation, use the Guangdong–Macao social-security one-window counter and confirm which of the 66+31 services apply to your employees’ situation.
  • Keep the 15% enterprise-income-tax and Macao-resident individual-income-tax preferences in view: Nansha says it will continue optimising these along with the second-phase implementation of the Nansha Plan.

Sources

  • 广州市南沙区人民政府 — 媒体”天团”探秘”湾区棋眼”跃升密码(南沙粤澳合作与”四通”机制): https://www.gzns.gov.cn/zwgk/zwdt/content/post_10981086.html
  • 南方+ — 打通四大互通通道,广州南沙”十五五”精准施策赋能澳门企业人才跨境发展: https://www.nfnews.com/content/X3RvwmeD3P.html
  • 澳门日报 — 南沙四方面深化粤澳合作(设备通、人畅通、资金通、生活通报道): https://www.macaodaily.com/html/2026-08/26/content_1929447.htm

Related reading

  • see also: Hengqin’s aviation logistics subsidy scheme — a new low-cost route for cross-border cargo (345-hengqin-aviation-logistics)
  • see also: Guangdong’s international medical services pilot (329-guangdong-international-medical-services)

南沙对澳”四通”框架:设备、人才、资金与生活

概述

2026年8月25日,中央港澳办”对接’十五五’发挥新优势”主题联合采访走进广州南沙。在座谈中,南沙开发区(自贸区南沙片区)管委会方面系统阐述了深化粤澳合作的”四通”框架:设备通、人畅通、资金通、生活通。

这一框架直接回应澳门第三个五年规划——其中明确提出”积极探索与南沙等地共建特色合作平台、研究粤澳共同建设汽车出海平台”。澳门规划中的这一句话,为南沙提供了具体工作议程,而南沙正把它转化为可落地的政策。

通道一——设备通

跨境科研常被设备卡住:与内地机构合作的澳门科学家,需要把仪器设备带入广东,并随项目推进灵活往返。南沙的答案是全国率先探索的减免税科研设备跨境流动监管创新,核心是”一次申请、项目内通用“备案模式。科研团队对一个项目完成一次申报,即可在整个研究周期内灵活跨境调配设备,只需按季度反馈使用情况。这消除了每次移动重新审批的摩擦,意在让澳门科研团队更愿意与内地伙伴在南沙开展联合项目。

通道二——人畅通

两条机制承载这一通道:

  • 职业资格。 南沙深入实施”湾区通”工程,打通标准认证、跨境执业、数据流动、通关出行等卡点。境外职业资格认可清单已扩至248项,并推行”先执业、后备案“模式——澳门专业人士无需等待事前审批周期即可在南沙执业,事后备案即可。
  • 社保与个税。 已在南沙工作且已参加澳门社会保障基金的澳门居民,可免于参加内地企业职工基本养老保险、失业保险;在南沙工作的澳门居民,其个人所得税税负超过澳门税负的部分免征。对澳门专业人士而言,这实质改善税后收入,并消除双重缴费问题。

通道三——资金通

南沙的金融叙事依托跨境贸易投资高水平开放试点,累计交易额已超过620亿美元。南沙要做强科创金融、产业链金融、供应链金融等特色金融体系,加速便利澳门企业来南沙发展的跨境资金往来。贸易端,南沙港构建起连接葡语系国家的完善航线网络,粤澳葡语国家优质食品供应链中心已落户南沙——这是澳门发挥中葡平台作用的务实桥梁。

通道四——生活通

最后一条通道解决的是”澳门人真能在南沙生活”的问题:

  • “粤澳社保一窗通”专窗可同时办理66项广东社保服务和31项澳门服务,包括澳门”两金五津”及中央公积金等跨境领取,并免除跨境汇款手续费。
  • “湾区社保通””港澳药械通”等配套把便利延伸至医疗——在南沙的澳门居民可用港澳注册的药品与医疗器械就医,并有相应保险衔接。
  • 南沙披露,区内已集聚港澳企业超3100家、港澳居民超1.1万名。

双方刻意用有人情味的方式表述这一努力:”制度的衔接是为了心灵的贴近,通道的打通是为了情谊的延续。”

对投资者的意义

对评估大湾区的港澳与外国企业而言,”四通”框架值得作为投资选址信号来解读:

  • 研发密集型企业得到”设备故事”。 若业务涉及携设备入境开展联合研究,”一次申请、项目内通用”试点相对其他地区逐次审批,是真实的运营优势。
  • 人才密集型企业应把个税与社保政策计入成本。 澳门居民个税免征与社保待遇直接降低聘用澳门人才的成本,对依赖澳门人才的专业服务、医疗与教育项目尤其重要。
  • 汽车出海与葡语市场玩家应关注管线。 拟议中的粤澳汽车出海平台与葡语国家供应链中心,表明南沙正把自己定位为大湾区对接澳门关联贸易通道的门户。
  • 社保一窗通降低”留人难”问题。 跨境福利领取与免费汇款降低了人员调动的个人成本,有助于提高把澳门员工迁至南沙的企业的留存率。

实务建议

  • 若企业与澳门机构开展联合科研,向南沙有关部门咨询免税科研设备备案模式及季度使用反馈要求。
  • 聘用澳门专业人士时,事先确认其澳门社保基金参保状态,并把内地社保豁免与个税差额优惠计入薪酬方案。
  • 关注汽车出海平台与葡语供应链中心的申报窗口与扶持办法。
  • 涉及员工迁居,使用”粤澳社保一窗通”,并确认66+31项服务中哪些适用于本企业员工情形。
  • 持续关注15%企业所得税与澳门居民个税优惠政策:南沙表示将随《南沙方案》第二阶段实施继续优化。

来源

  • 广州市南沙区人民政府 — 媒体”天团”探秘”湾区棋眼”跃升密码(南沙粤澳合作与”四通”机制): https://www.gzns.gov.cn/zwgk/zwdt/content/post_10981086.html
  • 南方+ — 打通四大互通通道,广州南沙”十五五”精准施策赋能澳门企业人才跨境发展: https://www.nfnews.com/content/X3RvwmeD3P.html
  • 澳门日报 — 南沙四方面深化粤澳合作(设备通、人畅通、资金通、生活通报道): https://www.macaodaily.com/html/2026-08/26/content_1929447.htm

相关阅读

  • 见:横琴航空物流扶持办法——跨境货物新通道(345-hengqin-aviation-logistics)
  • 见:广东国际医疗服务试点(329-guangdong-international-medical-services)

Declaring psychotropic drug imports and exports: NMPA-GACC Announcement 2026 No. 84

  • The National Medical Products Administration (NMPA) and the General Administration of Customs (GACC) jointly published Announcement 2026 No. 84 on 28 August 2026, providing the customs HS commodity numbers to reference when declaring import or export of newly controlled medicinal psychotropic substances.
    2026年8月28日,国家药监局与海关总署联合发布2026年第84号公告,就新列入管制范围的药用类精神药品的进出口申报,公布供通关申报参考的海关商品编号。
  • The announcement follows a separate joint decision by NMPA, the Ministry of Public Security and the National Health Commission adding three substances to the medicinal psychotropic substance catalogue: methoxyetomidate, leretomidate and sonanfetomide — with exceptions for drug preparations approved for marketing in China.
    公告之前,国家药监局、公安部、国家卫生健康委联合发布调整公告,将甲氧依托咪酯、乐瑞托咪酯、索安非托增列入药用类精神药品目录(在中国境内批准上市的相应药品制剂除外)。
  • The published commodity numbers cover only part of the controlled goods; importers and exporters whose actual goods fall outside the listed numbers must declare truthfully rather than assume exemption.
    公布的编号仅包含管制商品中的部分商品;实际进出口商品超出相关商品编号范围的,应当如实申报,而非推定不涉管制。
  • The rules anchor to the Drug Administration Law and the Customs Law: medicinal psychotropic substances remain subject to import/export permit and reporting disciplines administered by NMPA and customs.
    新规以《药品管理法》《海关法》为法律依据:药用类精神药品进出口仍适用由国家药监局与海关管理的准许证与申报纪律。
  • The announcement takes effect on 1 October 2026, giving pharmaceutical importers, exporters and CRO/logistics partners a one-month window to update screening and declaration procedures.
    公告自2026年10月1日起施行,为医药进出口企业、研发外包与物流伙伴留下约一个月时间更新筛查与申报流程。
  • For pharmaceutical companies shipping controlled APIs or finished drugs in or out of China, the practical task is to verify each SKU against the expanded catalogue and the new commodity numbers, and to keep records showing the actual substance and formulation status.
    对进出境受管制原料药或制剂的企业而言,实操要点是逐一核对产品品目是否落入扩围后的目录与新商品编号,并留存能证明实际物质与制剂状态的记录。

Declaring psychotropic drug imports and exports: NMPA-GACC Announcement 2026 No. 84 | 药用类精神药品进出口申报新规:国家药监局 海关总署2026年第84号公告解读

Overview

On 28 August 2026 the National Medical Products Administration (NMPA) and the General Administration of Customs (GACC) published Announcement 2026 No. 84 — Matters Concerning the Declaration of Import and Export of Medicinal Psychotropic Substances (国家药监局 海关总署关于药用类精神药品进出口申报事项的公告). The announcement sets out the customs HS commodity numbers to reference when declaring imports or exports of varieties that were recently added to the medicinal psychotropic substance catalogue, and takes effect on 1 October 2026.

The announcement sits on top of an earlier regulatory step: NMPA, the Ministry of Public Security and the National Health Commission jointly issued a decision adjusting the medicinal psychotropic substance catalogue, adding methoxyetomidate, leretomidate and sonanfetomide to the list — except for drug preparations containing these substances that have been approved for marketing in China. Announcement 2026 No. 84 was then issued under the Drug Administration Law and the Customs Law to give traders concrete reference numbers for customs declaration.

Why this matters

China exercises strict control over psychotropic substances under its drug-control system, and the import and export of such substances requires permits and compliant declaration. The significance of this announcement is twofold:

  1. The control scope just widened. Three substances — methoxyetomidate, leretomidate and sonanfetomide — have been added to the medicinal psychotropic substance catalogue. Any company shipping these substances into or out of China (outside the China-approved formulation carve-out) now falls within the controlled-substance regime.
  2. Customs now has published reference codes. By giving HS commodity numbers for the newly added varieties, NMPA and GACC intend to reduce ambiguity at the border so that declarations are consistent and shipments are not held up by classification disputes.

The key provisions

  • Reference commodity numbers. The announcement publishes the customs commodity numbers for the newly listed varieties, for reference in customs declaration.
  • Partial coverage. The announcement expressly states that the commodity numbers cover only *part* of the controlled goods. If the actual goods being imported or exported fall outside the listed commodity-number range, the declarant must still declare truthfully.
  • Legal basis. The announcement is issued under the Drug Administration Law, the Customs Law and related laws and regulations.
  • Effective date. 1 October 2026.

The honest-declaration clause is the operative discipline: the commodity numbers are a facilitation tool, not a safe harbour. A shipment containing a newly controlled substance but classified under a different HS number remains subject to the controlled-substance rules, and the declarant bears the duty to reflect the true nature of the goods.

Context: the wider psychotropic-substance framework

Medicinal psychotropic substances are regulated separately from narcotic drugs but within the same family of controlled-substance rules. Imports and exports generally require permits issued through the drug-administration system, and customs releases goods against those permits together with normal declaration documents. Companies trading in active pharmaceutical ingredients (APIs) or finished drugs that touch the controlled list must:

  • verify whether each product contains a catalogue substance;
  • confirm whether a China-approved formulation exception applies;
  • obtain the appropriate permits before shipment; and
  • declare accurately at customs using the published reference codes where applicable.

What companies should do before 1 October 2026

For pharmaceutical importers and exporters — including foreign companies shipping APIs into China for contract manufacturing, or exporting controlled finished products — the practical checklist is:

  • Re-screen the product portfolio. Compare every SKU in the import/export pipeline against the expanded medicinal psychotropic catalogue, paying attention to the three new substances by both Chinese and international names.
  • Map the formulation exception. The catalogue addition excludes drug preparations approved for marketing in China. Confirm whether the product you ship is such an approved preparation and keep supporting registration documents in the compliance file.
  • Update declaration masters. Where a controlled substance is involved, update product masters, customs-classification records and the reference commodity numbers so that declarations after 1 October use the correct codes.
  • Check permit status. Confirm that the necessary import/export permits are in place and that the responsible internal or third-party declarant understands the split of duties between NMPA permits and customs release.
  • Prepare for audits. Regulators and customs may test whether declared goods match actual substance content. Retain certificates of analysis, formulation sheets and supply-chain records that demonstrate the true state of each shipment.
  • Brief logistics and CRO partners. If a third party handles declaration or cross-border logistics, circulate the announcement so screening updates are applied across the chain, not only at the licence holder.

Practical notes for foreign pharmaceutical companies

Foreign companies most affected are those that supply or buy the three newly controlled substances — or that manufacture medicines where these substances appear as intermediates or impurities above applicable thresholds. Points worth noting:

  • The announcement is a border-declaration facilitation measure; it does not by itself change the permit regime, which continues to apply to controlled substances.
  • The “approved formulation” carve-out is narrow: it protects drug preparations approved for marketing in China, not raw substances or unapproved preparations.
  • Given the 1 October effective date, any shipment booked for late September and arriving in October should be screened under the new scope to avoid a compliance gap.

Sources

  • 国家药品监督管理局 — 国家药监局 海关总署关于药用类精神药品进出口申报事项的公告(2026年第84号): https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260902092356142.html
  • 中华人民共和国海关总署 — 政务公告列表(含2026年第84号、第128号、第129号等): http://www.customs.gov.cn/
  • 医药魔方 — 药用类精神药品进出口申报事项公告(品种与施行日期摘要): https://bydrug.pharmcube.com/news/detail/484ba2600ed6d80d29192ad8ba49dca8

Related reading

  • see also: China’s 2026 customs clearance guide for the ninth CIIE (370-ciie-2026-customs-clearance-guide)
  • see also: Guangdong’s international medical services pilot and pharma investment (329-guangdong-international-medical-services)

药用类精神药品进出口申报新规:国家药监局 海关总署2026年第84号公告解读

概述

2026年8月28日,国家药品监督管理局与海关总署联合发布《关于药用类精神药品进出口申报事项的公告》(2026年第84号),就近期增列入药用类精神药品目录的品种,公布供进出口通关申报参考的海关商品编号。公告自2026年10月1日起施行。

公告建立在更早一步的监管动作之上:国家药监局、公安部、国家卫生健康委联合发布调整药用类精神药品目录的公告,将甲氧依托咪酯、乐瑞托咪酯、索安非托增列入药用类精神药品目录(在中国境内批准上市的含上述物质的药品制剂除外)。随后,依据《药品管理法》《海关法》等法律法规,2026年第84号公告出台,为贸易企业提供具体的通关申报参考编号。

为何重要

中国在药物管制体系下对精神药品实行严格管控,此类物质的进出口需取得准许证并合规申报。本次公告的意义有二:

  1. 管制范围刚刚扩大。 甲氧依托咪酯、乐瑞托咪酯、索安非托三个品种被增列入药用类精神药品目录。任何将上述物质运入或运出中国的企业(中国批准上市制剂除外),如今均落入管制物质制度范畴。
  2. 海关有了公开的参考编码。 通过为新增品种提供海关商品编号,国家药监局与海关总署意在减少口岸的归类不确定性,使申报口径一致,避免货物因归类争议而被滞留。

主要条款

  • 参考商品编号。 公告公布新增列品种的海关商品编号,供通关申报参考。
  • 部分覆盖。 公告明确,公布的编号仅包含管制商品中的部分商品。实际进出口商品超出相关商品编号范围的,仍应当如实申报。
  • 法律依据。 公告依据《药品管理法》《海关法》等法律法规制定。
  • 施行日期。 2026年10月1日。

“如实申报”条款是操作性纪律:商品编号是便利工具,而非安全港。一批含有新管制物质但归入其他HS编码的货物,仍适用管制物质规则,申报人有义务如实反映货物的真实属性。

背景:更宽的精神药品监管框架

药用类精神药品与麻醉药品分列管制,但同属管制物质规则体系。其进出口一般需通过药监系统取得准许证,海关凭准许证及常规申报文件放行。经营涉及管制清单的原料药或制剂的贸易企业,必须:

  • 核实每个产品是否含有目录内物质;
  • 确认是否适用”中国批准上市制剂”例外;
  • 在发货前取得相应准许证;
  • 在口岸按公布的参考编码如实准确申报。

2026年10月1日前应做的事

对医药进出口企业——包括向中国境内合同生产方供应原料药、或出口受管制成品的外国公司——实用核查清单如下:

  • 重新筛查产品组合。 将进出境管线中的每个品目与扩围后的药用类精神药品目录逐一比对,重点关注三个新增品种(中英文名称均需核对)。
  • 核实制剂例外。 目录增列不包含在中国境内批准上市的药品制剂。请确认你所运产品是否属于此类获批制剂,并在合规档案中留存注册证明文件。
  • 更新申报主数据。 若涉及管制物质,更新产品主数据、海关归类记录与参考商品编号,确保10月1日后的申报使用正确编码。
  • 核查准许证状态。 确认必要的进出口准许证已就位,并让内部或第三方申报人清楚理解药监准许证与海关放行之间的职责分工。
  • 备妥审计材料。 监管部门与海关可能核查申报货物与实际物质含量是否一致。留存检验报告、制剂配方单与供应链记录,以证明每批货物的真实状态。
  • 同步物流与外包伙伴。 若由第三方代理申报或负责跨境物流,应转发公告,使筛查更新贯穿整个链条,而不只停留在持证人一端。

给外国药企的实务提示

受影响最大的外国公司,是那些供应或采购上述三种新管制物质的企业,或在其药品中将此类物质作为中间体、杂质(超过适用阈值)出现的企业。值得注意:

  • 本公告属口岸申报便利化措施,本身并不改变准许证制度,管制物质仍须适用该制度。
  • “批准制剂”例外范围较窄:它保护在中国获批上市的药品制剂,不涵盖原料物质或未获批制剂。
  • 鉴于10月1日生效,凡9月下旬订舱、10月到港的货物,都应按新范围筛查,避免出现合规空档。

来源

  • 国家药品监督管理局 — 国家药监局 海关总署关于药用类精神药品进出口申报事项的公告(2026年第84号): https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260902092356142.html
  • 中华人民共和国海关总署 — 政务公告列表(含2026年第84号、第128号、第129号等): http://www.customs.gov.cn/
  • 医药魔方 — 药用类精神药品进出口申报事项公告(品种与施行日期摘要): https://bydrug.pharmcube.com/news/detail/484ba2600ed6d80d29192ad8ba49dca8

相关阅读

  • 见:第九届进博会海关通关须知(370-ciie-2026-customs-clearance-guide)
  • 见:广东国际医疗服务试点与医药投资(329-guangdong-international-medical-services)

China’s New Food Shelf-Life Standard: What Foreign Food Businesses Need to Know

  • China’s first national standard dedicated to food shelf-life determination, GB/T 47141-2026, took effect on 1 August 2026, providing unified technical rules for setting, validating and managing the shelf life of food products.
    我国首部系统规范食品保质期确定与全流程管控的专项国家标准 GB/T 47141—2026《食品保质期确定指南》于 2026 年 8 月 1 日起正式实施,为食品保质期的设定、验证与管理提供了统一技术规则。
  • The standard addresses long-standing compliance gaps: shelf-life decisions made without sufficient basis, non-compliant label declarations, mismatches between storage conditions and declared shelf life, and lax handling of near-expiry stock.
    该标准直指行业长期存在的合规短板:保质期设定依据不足、标签标注不规范、贮存条件与保质期不匹配、临期食品处置不严谨等。
  • Food producers, importers and restaurant operators must re-examine how shelf life is determined for each SKU, align label wording with the standard’s methodology, and keep validation records that can stand up to regulatory inspection.
    食品生产企业、进口商和餐饮经营者须重新梳理每个 SKU 的保质期确定方法,使标签标注符合标准方法论,并留存经得起监管检查的验证记录。
  • A national “standards outreach” campaign launched in Beijing on 25 August 2026 signals that local market regulators will apply GB/T 47141-2026 as a benchmark for uniform enforcement.
    2026 年 8 月 25 日在北京启动的”国家标准走基层”宣贯活动表明,地方市场监管部门将以 GB/T 47141—2026 作为统一执法尺度的技术基准。
  • For foreign food businesses, the new standard interacts with existing import clearance rules: shelf-life claims on imported foods must be consistent with the label, the transport and storage chain, and the determination methods recognised under Chinese national standards.
    对外资食品企业而言,新标准与既有进口清关规则相互衔接:进口食品的保质期标注必须与标签、储运链条以及中国国家标准认可的确定方法保持一致。
  • Practical steps include mapping the standard’s workflow (influencing factors, shelf-life determination, verification methods and management systems) onto existing quality-management procedures and updating near-expiry stock disposal policies before the next round of supervision.
    实操要点包括:将标准的工作流程(影响因素、保质期确定、验证方法和管理制度)映射到既有质量管理程序中,并在下一轮监管前更新临期食品处置政策。

China’s New Food Shelf-Life Standard: What Foreign Food Businesses Need to Know | 中国食品保质期新国标:外资食品企业须知

Overview

On 1 August 2026, China’s first national standard dedicated to food shelf-life management, GB/T 47141-2026 “Guidelines for the Determination of Food Shelf Life” (《食品保质期确定指南》), officially took effect. Published on 28 January 2026, the standard was developed to close a longstanding regulatory gap: while the Food Safety Law and its implementing rules require food producers and operators to clearly mark shelf life and storage conditions, they did not specify a uniform technical methodology for how shelf life should be determined in the first place. The result was a patchwork of industry practice, supplier declarations and discretionary enforcement across provinces.

The standard is particularly relevant for foreign-invested food companies and importers because it touches every link of the supply chain that shelf-life claims depend on: formulation and packaging choices, storage and transport conditions, label wording, and the handling of near-expiry goods. Beijing’s municipal market regulation bureau, which hosted a national outreach and training event on 25 August 2026, reported that as of the end of 2025 the capital alone had more than 120,000 licensed food business entities, including about 53,000 catering operators. Nationwide, the standard provides the technical benchmark that local regulators will increasingly use to assess whether a producer’s shelf-life decision was “scientific and reasonable” — the phrase used in the Food Safety Law.

What the standard requires

GB/T 47141-2026 sets out, in a single framework, the general principles, influencing factors, working procedures, verification methods and management systems for determining food shelf life.

First, the standard identifies the factors that shelf life must be based on. These include product characteristics and formulation, packaging materials and sealing performance, processing and sterilisation methods, storage and transport temperature and humidity, and the expected conditions of consumer storage after purchase. Producers can no longer simply copy a shelf life from a similar product or rely on a supplier’s indicative claim without documenting the technical basis.

Second, it prescribes a determination workflow. The producer defines the product and its key quality indicators (such as sensory, physicochemical and microbiological indicators), designs shelf-life experiments or uses accelerated ageing and real-time storage data, then verifies the result against defined criteria. The standard is deliberately framework-style: it recognises both real-time and accelerated testing approaches and leaves room for industry-specific guidance to be layered on top.

Third, it requires validation records and management systems. Food business operators are expected to keep records that demonstrate how each product’s shelf life was set and verified, how storage conditions are monitored, and how near-expiry stock is identified, quarantined and disposed of. These records are the practical evidence that enforcement bodies will request during daily supervision inspections under the Measures for Daily Supervision and Inspection of Food Production and Operation.

How it affects imported and foreign-branded foods

For foreign companies, the new standard has three direct points of contact.

The first is label consistency. Under the current label rules, imported pre-packaged foods must declare a shelf life on the Chinese label, and that declaration must be consistent with the shelf life determined by the manufacturer. Where the foreign producer’s own shelf-life determination was based on different assumptions about storage and transport conditions than those encountered in the China supply chain — for example, a long ocean transit segment or a multi-tier distribution network — the imported label may no longer be defensible. Importers should document the shelf-life basis, the transport temperature profile, and any accelerated ageing data, and reconcile them with GB/T 47141-2026’s methodology.

The second is storage-condition alignment. The standard requires that the declared shelf life be matched to defined storage conditions. If a product is marked “store at room temperature” but the import clearance and warehousing chain cannot guarantee the assumed temperature range, the shelf-life claim becomes vulnerable. Importers and their customs brokers should review warehouse temperature monitoring records as part of the compliance file, not as an afterthought.

The third is near-expiry handling. Restaurants and retailers that sell imported foods are expected to implement clear policies for identifying and handling near-expiry stock. The Beijing outreach campaign highlighted that “improper handling of near-expiry food” was one of the persistent problems the standard is meant to cure. Foreign fast-food chains, cafés and supermarkets operating in China should update their internal stock-rotation and disposal procedures to align with the standard’s management-system expectations, and should be ready to demonstrate them in inspections.

Practical steps for compliance

  1. Map the standard’s framework onto your existing quality system. Identify which influencing factors are documented for each imported or locally produced SKU, and close gaps where shelf life was inherited from the supplier without verification.
  2. Reconcile label declarations with the determination methodology. For each product, ensure the label’s shelf life, storage conditions and any “best before” wording match the supporting documentation, including temperature data from the transport and warehousing chain.
  3. Keep verification records in China. Regulators will ask for records showing how shelf life was determined and validated. Even where the original experiments were performed overseas, maintain translated, accessible summaries together with the relevant certificates of analysis.
  4. Update near-expiry stock policies. Document how staff identify, segregate and dispose of near-expiry goods, and retain disposal records. This applies equally to importers selling to distributors and to end-market restaurants and retail outlets.
  5. Monitor local enforcement. As local bureaus roll out the “standards outreach” campaign and incorporate GB/T 47141-2026 into supervision, expect inspectors to test shelf-life documentation during routine checks, particularly for high-risk categories such as dairy, meat and prepared meals.

Related reading

  • Imported food registration and labelling requirements under the General Administration of Customs (GACC) regime, which interplay with shelf-life claims at the border.
  • The Food Safety Law and its 2025 amendment, which set the “scientific and reasonable” benchmark for shelf-life marking.
  • Near-expiry food disposal rules in individual provinces, which layer additional local obligations on top of the national standard.

Sources

  • 经济日报《聚焦食品保质期新标准 “国家标准走基层”宣贯活动在京举行》(2026-08-25): https://www.jingjiribao.cn/static/detail.jsp?id=678944
  • 国家市场监督管理总局 餐饮食品安全监督管理司: https://www.samr.gov.cn/spjys/index.html
  • 五河县人民政府《食品生产经营日常监督检查管理办法》: https://www.wuhe.gov.cn/zfxxgk/public/25451/53348857.html
  • 根河市人民政府《中华人民共和国食品安全法》: https://www.genhe.gov.cn/OpennessContent/show/459150.html

中国食品保质期新国标:外资食品企业须知

概述

2026 年 8 月 1 日,我国首部系统规范食品保质期管理的专项国家标准 GB/T 47141—2026《食品保质期确定指南》正式实施。该标准于 2026 年 1 月 28 日发布,旨在补齐长期存在的监管空白:虽然《食品安全法》及其实施规则要求食品生产者、经营者明确标注保质期和贮存条件,但并未规定保质期应当如何确定这一统一技术方法。此前各地在保质期问题上主要依赖行业惯例、供应商声明和各省自由裁量的执法口径,标准不统一的问题突出。

对外资食品企业和进口商而言,该标准之所以重要,是因为它触及保质期声明所依赖的供应链每个环节:配方与包装选择、储运条件、标签措辞以及临期商品处理。北京市市场监督管理局在 2026 年 8 月 25 日主办全国性宣贯培训活动时透露,截至 2025 年底,仅北京一地就有持证食品经营主体超过 12 万户,其中餐饮服务经营者约 5.3 万户。在全国范围内,该标准正在成为地方监管部门判断食品生产经营者保质期设定是否”科学合理”(《食品安全法》用语)的技术基准。

标准提出了什么要求

GB/T 47141—2026 以单一框架形式规定了食品保质期确定的总则、影响因素、工作流程、验证方法和管理制度。

首先,标准明确了保质期必须基于的因素。这些因素包括产品特性和配方、包装材料与密封性能、加工与灭菌方式、储运温湿度,以及购买后消费者储存的预期条件。生产者不能再简单地参照同类产品复制保质期,或者仅凭供应商的提示性声明,而不留任何技术依据。

其次,标准规定了确定流程。生产者须界定产品及其关键质量指标(如感官、理化、微生物指标),设计保质期试验或采用加速老化与实时储存数据,然后按既定准则验证结果。标准刻意采用框架式写法:同时认可实时试验与加速试验两种路径,并为行业专项指南的叠加留出空间。

第三,标准要求验证记录和管理制度。食品生产经营者须留存能够证明每个产品保质期如何设定与验证、贮存条件如何监控、临期库存如何识别、隔离与处置的记录。这些记录正是执法机构依据《食品生产经营日常监督检查管理办法》开展日常检查时索取的实务证据。

对进口食品和外资品牌的影响

对外资企业而言,新标准有三个直接触点。

第一是标签一致性。根据现行标签规则,进口预包装食品须在中文标签上标注保质期,且标注须与制造商确定的保质期一致。如果外国制造商确定保质期时所依据的储运条件假设与中国供应链实际情况不同——例如存在较长的海运段或多级分销网络——进口标签的保质期声明就可能站不住脚。进口商应留存保质期依据、运输温度曲线以及加速老化数据,并与 GB/T 47141—2026 的方法论进行核对。

第二是贮存条件匹配。标准要求标注的保质期与明确的贮存条件相匹配。如果产品标注”常温保存”,而进口清关和仓储链条无法保证假设的温度区间,保质期声明就会变得脆弱。进口商及其报关代理应在合规档案中一并审查仓库温度监控记录,而非事后补做。

第三是临期处理。销售进口食品的餐饮门店和零售企业须制定明确的临期商品识别与处置政策。北京宣贯活动明确指出,”临期食品处置不严谨”正是该标准希望根治的顽疾之一。在华经营的外资快餐连锁、咖啡馆和超市应及时更新内部库存轮转与处置流程,使之符合标准对管理制度的预期,并准备好在检查中予以展示。

合规实操要点

  1. 将标准框架映射到既有质量体系。逐项核对每个进口或本地生产 SKU 的影响因素是否有文档支撑,对直接沿用供应商声明、未经验证的保质期补上验证材料。
  2. 使标签声明与确定方法一致。对每个产品,确保标签上的保质期、贮存条件及”最佳食用日期”等措辞与支撑文档一致,包括储运链条的温度数据。
  3. 在中国留存验证记录。监管机关会索要保质期如何确定与验证的记录。即使原始试验在境外完成,也应在境内保存可读的中文摘要及相应检验报告。
  4. 更新临期库存政策。记录员工如何识别、隔离和处置临期商品,并留存处置凭证。这一要求同样适用于向经销商供货的进口商和终端餐饮、零售门店。
  5. 跟踪地方执法口径。随着地方局开展”标准走基层”宣贯并将 GB/T 47141—2026 纳入监督检查,预计检查人员会在例行检查中核查保质期文档,尤其是乳制品、肉类和预制菜等高危品类。

相关阅读

  • 海关总署体制下的进口食品注册与标签要求,其与保质期声明在边境环节相互衔接。
  • 《食品安全法》及其 2025 年修正案,为保质期标注确立了”科学合理”的基准。
  • 各省临期食品处置规则,在全国标准之上叠加了地方性义务。

来源

  • 经济日报《聚焦食品保质期新标准 “国家标准走基层”宣贯活动在京举行》(2026-08-25):https://www.jingjiribao.cn/static/detail.jsp?id=678944
  • 国家市场监督管理总局 餐饮食品安全监督管理司:https://www.samr.gov.cn/spjys/index.html
  • 五河县人民政府《食品生产经营日常监督检查管理办法》:https://www.wuhe.gov.cn/zfxxgk/public/25451/53348857.html
  • 根河市人民政府《中华人民共和国食品安全法》:https://www.genhe.gov.cn/OpennessContent/show/459150.html